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Meant to be an authoritative guide for psychiatrists and others interested in understanding and
applying ketamine psychedelic psychotherapy (KPP), this paper focuses on its pharmacology,
phenomenology, and clinical applications. Ketamine is a dissociative anesthetic widely used by
physicians and veterinarians in the United States. In addition to its anesthetic and dissociative
properties, ketamine also has a multitude of other psychological and pharmacological properties,
which include analgesic, sedative, neuroprotective, anxiolytic, antidepressant, stimulant, euphoriant,
and hallucinogenic effects. The literature on the clinical application of KPP is comprehensively
reviewed, practical advice for using KPP is given, and the pharmacology and phenomenology of
ketamine-induced psychedelic experiences are explored, including in relationship to transpersonal
healing and possible iatrogenic consequences of misuse of KPP.
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etamine is an extremely interesting substance,
especially from a transpersonal healing perspective, as it not only has a wide range of potential
clinical applications, including through what is here
called ketamine psychedelic psychotherapy (KPP), but
it is the only legally-available (i.e., through a physician’s
off-label prescription without having to go through
regulatory hurdles) substance within the United States
that can reliably produce psychedelic experiences.
Consequently, we review the literature on the clinical
application of KPP, and focus on the phenomenology
of ketamine-induced psychedelic experiences in terms
of possible clinical applications within a transpersonal
context.
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Arylcyclohexylamines:
Ketamine’s Family Tree
he arylcyclohexylamines (also known as arylcyclohexamines or arylcyclohexanamines) were originally
developed as anesthetics by Parke-Davis. Unlike all
other anesthetic agents, except perhaps nitrous oxide,
the arylcyclohexylamines do not generally extinguish
consciousness, but instead appear to “dissociate” mind
from body (thus the name of “dissociative anesthetics”).
The arylcyclohexylamines predominantly block the
N-methyl-D-aspartate (NMDA) receptor, a target for
the neurotransmitter glutamate in the brain, and prevent
the NMDA receptor from being activated by glutamate
(Ahmadi & Mahmoudi, 2005; Ahmadi, Khalili,
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Hajikhani, & Naserbakht, 2011). In addition to NMDA
antagonism, the arylcyclohexylamines produce µ opioid
receptor agonism (Itzhak & Simon, 1984) and cause
dopamine reuptake inhibition (Chaudieu et al., 1989).
Some of the arylcyclohexylamines also produce sigma
receptor agonistic (He et al., 1993), nACh receptor
antagonistic (Eterović et al., 1999), and D2 receptor
agonistic (Seeman, Ko, & Tallerico, 2005) actions.
Antagonism of the NMDA receptor generates
dissociative (hallucinogenic), anesthetic, neuroprotective
and anticonvulsant effects; stimulation of the sigma
and D2 receptors contributes to hallucinogenic
(psychomimetic) effects; activation of the µ-opioid
receptor causes analgesic and anxiolytic effects; blockade
of the dopamine transporter mediates stimulant and
euphoriant effects (as well as adding to psychomimetic
effects in higher doses); the combination of the two last
qualities confers a strong antidepressant effect; and the
combination of all the above pharmacological properties
make the arylcyclohexylamines powerful psychedelic
drugs.
The first member of the arylcyclohexylamine class
to be discovered was phencyclidine. It was synthesized in
1926, eventually patented in 1953 by the Parke-Davis
pharmaceutical company for use as an anesthetic agent
for humans and animals, and was marketed under the
brand name Sernyl ® (referring to serenity). By 1965, its
use with humans was discontinued as clinical studies
revealed that patients experienced what was then seen as
“psychotic” symptoms when emerging from the drug’s
effects (so-called “emergence delirium”). Today, it is
rarely used even in the veterinary community. However,
it continues to be legally available for research purposes
in the United States, but as a Schedule II controlled
substance.
Phencyclidine re-emerged as a drug of abuse
in the mid-1960s due to its strong euphoriant and
psychedelic qualities. The drug was relatively easy and
inexpensive to manufacture in clandestine laboratories
and it quickly became popular on the streets, with names
such as “Angel Dust” and PCP. PCP can be pressed into
pills or put in capsules and swallowed. When ingested
orally, effects are felt in 30 to 45 minutes and last from 6
to 24 hours. Doses of less than 5 mg produce euphoriant
effects (feelings of elation and joy, relaxation, feelings of
unreality and mild dissociation from the environment),
while doses of 10 mg or more produce psychedelic effects
(distorted sense of one’s body, a feeling of weightlessness,

distorted sense of time and space, visual and auditory
hallucinations).
PCP use spread in the 1970s. When PCP is
snorted or smoked (for example, users dipped tobacco
or cannabis cigarettes in the liquid form of PCP or
sprinkled its powder form on a leafy material like
tobacco or cannabis), the effects are felt within 4 to 5
minutes and last from 4 to 6 hours. PCP can also be
injected, although this appears to be a less common
route of administration.
PCP use may have peaked around 1978, when
People magazine called it the country’s “number one”
drug problem. PCP became infamous for its recurrent
binges (so-called “runs”), when chronic users would
take PCP repeatedly for 2 to 3 consecutive days at a
time without eating or sleeping. It was estimated that
at least 7 million Americans used PCP on at least
one occasion between 1975 and 1983. The American
Psychiatric Association (APA) Diagnostic and Statistical
Manual (DSM)-IV-TR (APA, 2000) devoted a separate
chapter to this substance entitled Phencyclidine-Related
Disorder. By the mid-1980s, PCP use began declining,
perhaps partly as a result of the increased popularity of
ketamine and crack cocaine. Eventually, PCP use slowly
faded away, although there is still some manufacture
by clandestine chemists. Today PCP is classified as a
hallucinogen and the new APA (2013) DSM-5 places its
effects in the Hallucinogen-Related Disorder category,
with classical hallucinogens.
The second compound from the arylcyclohexylamines class, eticyclidine, was also developed by
Parke-Davis and evaluated for anesthetic potential
under the code name CI-400. Eticlydine is very similar
in effects to phencyclidine and is slightly more potent.
Parke-Davis did not continue its research of eticyclidine
after the development of ketamine, a similar drug with
more favorable properties. Nevertheless, eticyclidine
(under the name of PCE) did make its way to the
streets and was briefly abused in the 1970s and 1980s.
It did not become popular with recreational users due
to its unpleasant taste and tendency to cause nausea.
Eticyclidine was placed into the U.S. Schedule I list of
illegal drugs in the 1970s and its use is unknown today.
Ketamine was the third compound from the
class of arylcyclohexylamines that Parke-Davis developed
as part of an effort to find a safer and more predictable
anesthetic agent than its precursors. Unlike the first
two creations of Parke-Davis, ketamine proved to be
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the most promising compound and eventually became
the company’s most successful anesthetic, sedative,
analgesic, anxiolytic, and neuroprotective agent.
Ketamine Pharmacology
etamine hydrochloride, a phencyclidine derivative,
was originally invented in 1962 by the American
organic chemist Calvin Stevens, who initially
called the compound CI-581 and later renamed it
ketamine. Ketamine, like all the arylcyclohexylamines,
predominantly targets the neurotransmitter glutamate,
which is an excitatory messenger that turns on the
brain cells and triggers an electrical impulse. Ketamine
opposes this action by blocking the N-methyl-D-aspartate
(NMDA) receptor. It prevents the NMDA receptor from
being activated by glutamate (Anish, Berry, Burton, &
Lodge, 1983; Thomson, West, & Lodge, 1985). Ketamine
also has direct and/or indirect effects on the µ opioid
(Fink & Nagai, 1982; Fidecka, 1987; Freya, Latish,
Schmidhammer, & Portoghese, 1994; Herman, Vocci, &
Bridge, 1995; Latasch & Freye, 1993; Smith et al., 1980;
Winters et al., 1988), dopamine (French, Mura, & Wang,
1993; Irifune, Shimizu, & Nomoto, 1991; Irifune et al.,
1997; Keita, Lecharny, Henzel, Desmonts, & Mantz,
1996; Nishimura & Sato, 1999; Rao, Kim, Lehmann,
Martin, & Wood, 1990), serotonin (Kim, Park, & Park,
1998; Lindefors et al., 1997; Martin, 1982; Minami,
Minami, & Harris, 1997; Pallotta, Segieth, & Whitton,
1998), acetylcholine (Cohen, Chan, & Trevor, 1973;
Durieux & Nietgen, 1997; Mimura et al., 1992; Morita
et al., 1995; Toro-Matos, Rendon-Platas, Avila-Valdez,
& Villarreal-Guzman, 1980), GABA (Drejer & Honore,
1987; Lindefors et al., 1997), cannabinoid (Richardson,
Aanonsen, & Hargreaves, 1998; Stella, Schweitzer, &
Piomelli, 1997), nitric oxide (Abajian, Page, & Morgan,
1973; Carroll, Lac, Asencio, & Kragh, 1990; Galley &
Webster, 1996; Lin, Chiou, & Wang, 1996) and sigma
(Hustveit, Maurset, & Oye, 1995) systems.
Ketamine hydrochloride may be administered
via a variety of routes including oral, sublingual, rectal,
intranasal, intramuscular, and intravenous routes.
Ketamine is a highly lipid soluble chemical and, as a
result, its clinical effects present within 45 to 50 seconds
of administration when given intravenously, within
3 to 4 minutes when given intramuscularly, within
5 to 10 minutes when given intranasally, and within
20 to 30 minutes when given orally (Alonso-Serra &
Wesley, 2003). The 1992 version of the Physicians’ Desk
Reference (PDR) indicated that ketamine use is usually
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devoid of life-threatening side-effects and that several
instances of unintentional administration of overdoses
of ketamine of up to ten times that usually required for
surgical anesthesia have been followed by prolonged but
complete recovery (PDR Network, 1992).
More than 10,000 published reports describe
ketamine’s high level of effectiveness and its confirmed
biological safety in most cases, although like all drugs
there is the possibility of some adverse effects in some
people (Bauman, Kish, Baumann, & Politis, 1999; Dachs
& Innes, 1997; Ersek, 2004; Reich & Silvay, 1989; Ross
& Fochtman, 1995; Shapiro, Wyte, & Harris, 1972).
Clinical studies have generally detected no long-term
impairment of behavior or personality functioning as
a result of repeated ketamine use (Siegal, 1978), but
some individual case studies of ketamine dependence
have raised questions at times (e.g., Jansen 1990, 2000,
summary in Jansen 2001) and there have been some
recent concerns about, for example, toxicity to the urinary
system (e.g., Selby et al., 2008; Wood, 2013.)
According to several in vitro and animal studies,
ketamine can even have neuroprotective properties under
some circumstances (Hoffman et al., 1992; Shapira,
Artru, & Lam, 1992; Shapira, Lam, Eng, Laohaprasit,
& Michel, 1994). Subsequently, ketamine has been used
as a neuroprotective agent to prevent brain damage from
head trauma, strokes, heart attacks, epileptic seizures, low
oxygen levels, and low blood-sugar levels (Albanese et al.,
1997; Bar-Joseph, Guilburd, Tamir, & Guilburd, 2009;
Filanovsky, Miller, & Kao, 2010; Hirota & Lambert,
1996; Hughes, 2011; Mayberg, Lam, Matta, Domino, &
Winn, 1995; Rothman et al., 1987; Shapira et al., 1994;
Weiss, Goldberg, & Choi, 1986).
Ketamine Biochemistry
and Electrophysiology
xtensive research of the biochemical aspects of
ketamine has been done by one of us, a Russian
researcher, Evgeny Krupitsky, and a U.S. researcher, John
Krystal, who both have conducted extensive independent
studies since the 1980s. Krupitsky and Krystal later
collaborated in researching the biochemistry of ketamine
(Krupitsky et al., 2001; Krystal et al., 2003a).
Krupitsky conducted ketamine studies at the
Center for Research in Addiction and Psychopharmacology in St. Petersburg, Russia, researching the effects
of ketamine administration on metabolism of biogenic
amines, including dopamine, serotonin, monoamine
oxidase type A (MAO-A), monoamine oxidase type B
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(MAO-B), GABA, ceruloplasmin, and B-endorphin.
The results of these biochemical investigations show
that during the ketamine session, dopamine levels were
increased, serotonin and GABA concentrations were
not altered significantly, ceruloplasmin activity and the
B-endorphin levels were increased, and the activity of
MAO-A in blood serum and MAO-B in blood platelets
significantly decreased. The results provided biochemical
data showing that the pharmacological actions of
ketamine affect monoaminergic and opioidergic
neurotransmitter metabolism (Krupitsky et al., 1990).
These changes in the metabolism of
neurotransmitters allow some opinions to be formed
about the underlying neu
rochemical mechanisms of
ketamine’s psychedelic action. For example, an increase
of ceruloplasmin activity causes a corresponding increase
in the conversion of monoamines into adrenochromes,
which have hallucinogenic activity (Anokhina, 1975;
Nalbandyan, 1986). This particularly takes place under
the conditions of inhibited MAO activity and increased
dopamine levels. This is of interest because such
conditions are typical for the action of many classical
hallucinogens (Hamox, 1984; McKenna, Towers,
& Abbott, 1984). The fact that the pharmacological
actions of ketamine affected both monoaminergic and
opioidergic systems, two neurochemical systems involved
in pathogenesis of alcoholism, is an important result of
this biochemical investigation, as it is possible that these
actions contribute to the efficacy of KPP.
Krupitsky has also used EEG computer-assisted
data in studying underlying mechanisms of KPP
(Krupitsky & Grinenko, 1997). EEG recordings were
taken before, during, and after the ketamine session
by placing 16 electrodes according to the international
scheme. After analog-digital conversion, standard
programs of computer assisted spectral EEG analysis
and topographic mapping of EEG were employed. The
data of EEG computer-assisted analysis demonstrated
that ketamine increases deltaactivity (1.5 – 2X) and
particularly theta-activity (3 – 4X) in all regions of
the cerebral cortex. This is evidence of limbic system
activation during ketamine sessions, as well as evidence
of the reinforcement of the limbic cortex interaction
(Pribram, 1971). These findings can also be considered to
a certain extent as indirect evidence of the strengthening
of the interactions between the so-called conscious and
unconscious levels of the mind during KPP (Simonov,
1987).

There are also some data indicating that the
interaction between the frontal cortex and the limbic
system are important for the action of ketamine on the
brain. Previously, it has been demonstrated in positron
emission tomography (PET) with fluorodeoxyglucose
(FDG) studies that ketamine-induced disturbances of
glutamatergic neurotransmission results in a specific
hyperfrontal metabolic pattern in the human brain
associated with psychedelic experiences, specifically
visionary experience and ego-dissolution (Vollenweider
et al., 1994). Also, frontal lobotomy reduces the
psychedelic response to phencyclidine in schizo
phrenic patients (Itil, Keskiner, Kiremitci, & Holden,
1967). Ketamine activates the interaction between
brain structures associated with cogni
tive processing
of information (frontal cortex) and structures involved
in the processes of emotions, motivations, memory,
and subconscious experiences and perceptions (limbic
struc
tures). Such enhanced interaction may be an
important neurophysiological mechanism underlying
the phenomenology of ketamine psychedelic experiences
and the dramatic psychological changes caused by those
experiences.
John Krystal, chair of the department of
psychiatry at Yale University School of Medicine, directed
ketamine research at the Connecticut Mental Health
Center in New Haven. He utilized ketamine primarily
as a psychomimetic agent to study the neurobiology of
schizophrenia, and focused on ketamine’s effects on
perceptual and cognitive functioning (Krystal et al.,
1994, 1998a, 1998b, 1999, 2000). Krystal’s group also
collected a substantial body of evidence demonstrating
that ketamine’s major underlying mechanism of action
on the brain is the blockade of the N-methyl-D-asparate
(NMDA) receptors, which are mostly located in the
cortex and hippocampus and are involved in processes of
integration and transmission into the cortex of incoming
signals from all sensory modalities (Krystal et al.,
1994). This finding was confirmed by another group of
investigators (Oye, Paulsen, & Maurset, 1992), verifying
that a significant reduction of sensory transmission and
activation of autonomous cortex-limbic interactions may
be important underlying mechanisms of the psychedelic
action of ketamine.
In addition, Krystal’s group completed clinical
research studying the effect of ketamine’s NMDA
glutamate receptor antagonist response in recovering
ethanol-dependent patients (Krystal et al., 1998b).
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Twenty male patients with alcoholism who had not
consumed alcohol for 10 days to 4 weeks prior to the study
completed 3 test days that involved the administration of
very low (0.1 mg/kg) and low-to-medium (0.5 mg/kg)
doses of ketamine or saline solution under randomized
double-blind conditions. Ethanol-like subjective effects
were assessed using visual analog scales to measure
“high” and degree of similarity to ethanol, cocaine, and
cannabis, and also employed a scale assessing the number
of standard alcohol drinks producing similar subjective
effects. This team concluded that ketamine produced
ethanol-like effects in a dose-related way on each scale,
exhibiting similarity to ethanol. However, its effects
were judged more similar to the sedative, rather than
stimulant, alcohol effects. Ketamine effects also were
more like ethanol than cannabis or cocaine. Ethanollike effects were more prominent at the higher ketamine
dose, a dose rated as similar to greater levels of ethanol
intoxication. The production of ethanol-like subjective
effects by ketamine supports the potential clinical
importance of NMDA receptor antagonism among the
mechanisms underlying the subjective effects of ethanol
in humans (Krystal et al., 1998b; Krystal et al., 2003b).
Ketamine Development
n 1964, ketamine was officially tested on the first
human subjects, the inmates at the Jackson Prison in
the State of Michigan. The study was done by Edward
Domino, MD, an American clinical pharmacologist
(Domino, Chodoff, & Corssen, 1965). Domino was the
first investigator to discover that ketamine has multiple
pharmacological effects, including anesthetic, analgesic,
and antidepressant effects.
Domino was also the first researcher who
discovered the “schizophrenomimetic” (hallucinogenic)
properties of ketamine. He reported that most of his
subjects described strange experiences like feeling
“spaced out” and “floating” (Domino, 2010). Initially,
Domino used the word “dreaming” to describe the
drug’s hallucinogenic effect. However, the Parke-Davis
scientists did not like that name out of the company’s
concerns that the U.S. Food and Drug Administration
(FDA) may label ketamine as “psychotomimetic,” which
might stop the clinical development of a very promising
pharmaceutical. Domino discussed the unusual actions
of ketamine with his wife and mentioned that the
subjects were “disconnected” from their environment.
His wife came up with the term “dissociative anesthetic”
that “dissociates” so-called mind from body (Domino,
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2010). From that time, the “dissociative anesthetic”
name has been assigned not only to ketamine
hydrochloride, but also to the entire class of psychoactive
arylcyclohexylamines.
In 1966, Parke-Davis patented ketamine under
the brand name Ketalar for use as an anesthetic in
humans and animals. Ketamine was successfully tried
on American soldiers in the Vietnam War (when it
got nicknamed the “buddy drug” because it could be
administered by a corpsman or a fellow soldier due to its
relative safety and ease of administration). In the course
of the Vietnam War, it became the most widely used
battlefield anesthetic, sedative, and analgesic, giving an
excellent opportunity for American anesthesiologists
and surgeons to become familiar with the agent.
Ketamine rapidly became the drug of the choice
used by the U.S. military for CASEVAC, a military term
for the emergency patient evacuation of casualties from
a combat zone to a clearing station or a nearby hospital,
increasingly by helicopter in the jungle wars. In most
cases a wounded soldier would be in a hospital receiving
medical care within 35 minutes of being wounded.
Patients were moved directly from the battlefield directly
into the preoperative and resuscitation shelter while
under the effects of field-administered ketamine.
Impressively, the use of ketamine as an agent
for analgesia and conscious sedation during battlefieldcasualty evacuations helped to decrease the mortality rate
of wounded soldiers who made it to medical treatment
from 4.5% during the Korean War to 2.6% during the
Vietnam War. The U.S. soldiers knew that, if they were
wounded, they had a better chance of surviving and
quickly receiving medical care than in any other war
in which the United States had previously participated,
a fact that did much to boost troop morale (Vietnam
Studies, Department of the Army, 1973).
Eventually, in 1970, the FDA approved the use
of ketamine anesthesia with children, adults, and the
elderly. Since that time, ketamine has been widely used in
hospitals and for office procedures due to its rapid onset,
short duration of action, and superior safety. Ketamine
has now been in clinical practice for 50 years and has
been continually used as a usually very safe anesthetic
to evoke general anesthesia, a first line agent to induce
procedural conscious sedation, a potent non-opiate
analgesic to control both acute and chronic pain, a unique
neuroprotective agent to prevent brain damage, a superior
anxiolytic to control preoperative and end-of-life anxiety,
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a rapid-onset antidepressant to treat chronic depression
and other treatment-resistant psychiatric conditions, and,
for a period, the only legal hallucinogenic drug available
to conduct psychedelic psychotherapy (although there
has been some forward movement in that regard in recent
years, with some work recommencing using substances
such as psilocybin and DMT; Friedman, 2006).
Unsurprisingly, ketamine has also become
popular on “the streets” for its strong euphoriant effects
and potent hallucinogenic properties. There are some
matters of relevance to therapeutic issues to be learned
from its non-medical and “recreational” use, so this
paper also reviews some of that material.
Ketamine Pharmacotherapy
t has been proposed (Haas & Harper, 1992; White, Way,
& Trevor, 1982) that the “ideal” agent for anesthesia
must possess the following specific characteristics:

A few classes of drugs, such as the opioids, barbiturates,
and benzodiazepines, meet some, but not all, of these
criteria. Today, ketamine is one of only a very few agents
that regularly meets all of these criteria of an ideal
anesthetic, when the dose is suitable for the patient and
purpose. Certainly a large bolus dose of ketamine as
a sudden intravenous push can affect respiration and
intracranial pressure, but in that instance it can often be
argued that the dose was not suitable for the patient and
purpose. Ketamine is included in the 18th edition of the
World Health Organization (2013) model list of essential
medicines, promulgating its availability in a health system.
It has been a half a century since Domino
administered ketamine to the first human subjects
(Domino et al., 1965). Since then, ketamine has
become widely accepted as an outstanding agent to
reduce preoperative anxiety and facilitate induction of

general anesthesia, as it appears to have virtually all of
the desired properties of the ideal agent. Subsequently,
ketamine has been used worldwide for an extensive range
of various procedures, including preoperative sedation,
intraoperative anesthesia, and postoperative analgesia
(Haas & Harper, 1992).
While there are many anesthetic drugs available,
internationally ketamine remains amongst the most
popular general anesthetics, especially in the Developing
World and emergency contexts, because of its low cost,
ease of storage, advantageous airway and respiratory
properties, hemodynamic stability, broad range of
clinical applications, and excellent therapeutic index
(Craven, 2007; USAARL Report, 2010). Ketamine’s
wide-therapeutic window (Green, Clem, & Rothrock,
1996; Green et al., 1999; Strayer & Nelson, 2008)
makes it the anesthetic of choice in austere or resourcepoor environments where monitoring equipment
may be rudimentary or absent and a single operator
must provide the anesthetic and monitor a patient
(Green et al., 1996; Strayer & Nelson, 2008). It can be
administered via almost any route, although intravenous
(IV) and intramuscular (IM) administrations are by far
the most popular and best studied for surgical anesthesia
(Mistry & Nahata, 2005). The initial dose of ketamine
administered intravenously ranges from 1 mg/kg – 4.5
mg/kg, and intramuscular doses range from 6.5 – 13 mg/
kg (White et al., 1982). Ketamine is highly lipid soluble
and, as such, clinical effects present within one minute
of administration when given intravenously and within
five minutes when given intramuscularly (Alonso-Serra
& Wesley, 2003).
Today, the most frequent use of ketamine has
been for conscious sedation for physically or emotionally
painful procedures (procedural sedation) and analgesia
for acute and chronic pain, both on the battlefield
and in emergency departments worldwide, and also in
vetinary medicine. For use in sedation only, the doses
of ketamine are 0.5 – 0.75 mg/kg IV or 2 – 4 mg/kg
IM; for use as an analgesic and/or anxiolytic agent, the
doses of ketamine are 0.2 – 0.3 mg/kg IV, 0.5 – 1.5 mg/
kg IM and intranasal, and 1 – 2 mg/kg sublingual, oral
and rectal.
Peak plasma concentrations have been reported
to occur within 1 min following IV administration,
5 to 15 minutes following IM injection, 30 minutes
after oral administration and 45 minutes after rectal
administration (Domino et al., 1984; Grant, Nimmo,
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Effective in inducing anesthesia
Minimal cardiovascular effects
Minimal respiratory effects
Ability to titrate
Rapid onset of action
Predictable duration of effect
Short elimination half-life
Anxiolytic at sub-anesthetic doses
Analgesic in sub-anesthetic doses
Soluble in water
Stable in solution
Absence of pain on injection
Absence of post-injection irritation.

& Clements, 1981; Pedraz et al., 1989). Elimination is
primarily by the kidney, and only a small percentage is
recovered in the urine as the unchanged drug (Chang,
Savory, & Albin, 1970). The elimination half-life of
ketamine is approximately 2 hours (Domino et al., 1984),
although there are some longer estimates. Metabolites
which are also active NMDA receptor blockers can
sometimes be detected in urine for up to a week or more
(e.g., Ebert, Mikkelsen, Thorkildsen, & Borgbjerg, 1997.)
When ketamine is administered in small
(analgesic, anxiolytic, and sedative) doses, it does not
usually impair spontaneous respirations and does not
increase blood pressure and heart rate (Subramaniam,
Subramaniam, & Steinbrook., 2004; Visser & Schug,
2006; White et al., 1982), which makes ketamine an
especially desirable analgesic/anxiolytic/sedative for
use on the battlefield and in evacuation procedures.
Today, combat medics continue using ketamine for
battlefield sedation and pain management because of its
minimal impact on medic carrying capacity and ability
to withstand environmental extremes. It is also much
more field expedient than any other analgesic due to
its low occurrence of side effects (Guldner, Petinaux,
Clemens, Foster, & Antoine, 2006). In a recent review of
analgesic options for pain relief on the battlefield, Black
and McManus (2009) wrote that, in sub-anesthetic doses,
ketamine is almost ideal as an analgesic due to providing
profound-pain relief, potentiating opioids, preventing
opioid hyperalgesia, and its margin of safety.
The use of ketamine by emergency physicians
prior to the 1990s was infrequent (Green & Krauss,
2004a, 2004b). However, after a landmark study by
Green and Johnson (1990), it has become one of the most
popular agents for procedural sedation and analgesia
in emergency departments. In their review of 11,589
administrations of ketamine for sedation, Green and
Johnson (1990) firmly established the drug’s safety and
efficacy for medical use.
Since then, ketamine has been extensively used
as an analgesic in intensive and acute care medicine
(particularly in emergency medicine), and there has
been considerable further research on the efficacy, safety,
contraindications, guidelines, and dosing of ketamine
(Green & Krauss, 2004a, 2004b; Lin & Durieux, 2005;
Mistry & Nahata, 2005). It has been well documented
that ketamine has a very low frequency of adverse effects
in doses used for conscious sedation and analgesia
(Alonso-Serra & Wesley, 2003; Cherry, Plummer,
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Gourlay, Coates, & Odgers, 1995; Howes, 2004;
Jennings, Cameron, & Bernard, 2011; Porter, 2004).
Today ketamine is routinely stocked in all emergency
departments across the United States, Australia, New
Zealand, and many other countries (Sacchetti, Senula,
Strickland, & Dubin, 2007); due to its exceptional
analgesic and sedative properties at low doses, ketamine
has been widely used for treatment of acute postoperative
pain, so-called breakthrough pain in patients with acute
and/or chronic pain, and for management of neuropathic
pain disorder, ischaemic limb pain disorder, refractory
cancer pain, and as a pediatric sedation tool for use with
acutely injured children (Bell, Dahl, Moore, & Kalso,
2006; Buvanendran & Kroin, 2009; Carr et al., 2004;
Ellis, Husain, Saetta, & Walker, 2004; Green & Krauss.,
2004a, 2004b; Howes, 2004; McGlone, Howes, &
Joshi, 2004; Petrack, Marx, & Wright, 1996; Rakhee
& Milap, 2005; Schmid Sandler, & Katz, 1999; Visser
& Schug, 2006). In addition, low-dose ketamine has
successfully served as an effective adjunct to standard
opioid therapy, as well as an adjunct to various nonopiate analgesic agents (Schmid, Sandler, & Katz, 1999).
One of the reasons ketamine has been
repeatedly studied and scrutinized is its uniqueness
among all other sedatives, hypnotics, and analgesics
(primarily opiates, barbiturates, and benzodiazepines).
The standard definition of conscious procedural sedation
is dose-dependent alterations in consciousness that result
in mild to deep sedation, preserving responsiveness to
verbal or tactile stimuli. Ketamine, in contrast, exerts
its effect through a functional and electrophysiological
dissociation or disconnect between the thalamoneocortical and limbic areas of the brain (Green &
Krauss, 2004a, 2004b; Krupitsky & Grinenko, 1997;
Mistry & Nahata, 2005). Therefore, it does not have a
characteristic dose-response continuum by progressive
titration; the dissociation is present or absent with a
very narrow transition zone (Mistry & Nahata, 2005).
At doses below a certain threshold, ketamine produces
analgesia and anxiolysis; however, once the critical dosage
threshold of roughly 1 – 1.5 mg/kg IM (or 0.5 – 0.75
mg/kg IV) is reached, the characteristic dissociative state
abruptly appears (Krauss & Green, 2006). Furthermore,
dissociation is described as a “trance-like cataleptic
state” of “sensory isolation” (Mistry & Nahata, 2005),
meaning little or no responsiveness is present.
Most importantly, unlike other traditional
sedatives, ketamine usually preserves cardiovascular
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stability, spontaneous respirations and protective airway
reflexes, even when exerting its full effect (Green &
Krauss, 2004a, 2004b; Mistry & Nahata, 2005).
Because of this, the dissociative state is not consistent
with the definitions of conscious sedation (Green &
Krauss, 2004a, 2004b; Krauss & Green, 2000, 2006),
which has resulted in a separate definition for ketamine
procedural sedation, namely “dissociative sedation”
(American College of Emergency Physicians, 2005).
It should be noted that ketamine is a nonreversible
agent; once the dissociative state is initiated, it cannot
be aborted (Alonso-Serra & Wesley, 2003; White et al.,
1982).
Ketamine performs as a superior fast-acting
analgesic and anxiolytic in low doses (0.2 – 0.3 mg/kg
IV, 0.5 – 1 mg/kg IM and intranasal, and 1 – 2 mg/kg
sublingual and oral), as an effective reliable sedative in
medium doses (0.5 – 0.75 mg/kg IV, 1.5 – 4 mg/kg IM),
and a safe short-acting anesthetic in high doses (1 – 4.5
mg/kg IV and 6.5 – 13 mg/kg IM).
Ketamine-Induced Emergence Phenomena
lthough ketamine is biologically safe in most
instances of medical use and has an excellent safety
profile, it is not without controversy, as it generates
peculiar psychological side-effects (vivid imagery,
visual hallucinations, excitement, irrational behavior)
dubbed “emergence delirium,” it has a high dependence
potential when abused, and use in a drug-abuse context
has recently resulted in multiple reports of harm to
the kidney and bladder (cystitis) in some people (e.g.,
Bokor & Anderson 2014; Meng et al., 2013; Selby et al.,
2008; Tam et al., 2014; Wood, 2013). This has become
a fairly hot topic in, for example, Hong Kong urology,
where ketamine abuse is rife, but appears not to have
been specifically reported by long-term heavy users of
medically-sourced ketamine such as John Lilly, and
those who contributed to one of our author’s (Jansen,
2001) book, Ketamine: Dreams And Realities. However,
some of the latter did complain of mysterious “K pains”
in the pelvic region, and it seems increasingly likely
that these persons may have been susceptible to these
urological issues as the evidence continues to mount,
from multiple medical specialists in multiple countries,
that some long-term heavy users are susceptible to
urological side-effects. There have also now been animal
studies pointing to a mechanism (e.g., Gu et al., 2014),
so this is unlikely to be one of those random panics that
have characterised the War on Drugs (e.g., scare tactics,

such as “LSD damages your chromososmes”) that were
later discredited as propaganda (Dishotsky, Loughman,
Mogar, & Lipscomb, 1971.)
Domino was the first clinician who documented
that 30% of patients had an “emergence delirium”
after ketamine anesthesia (Domino et al., 1965).
Subsequently, he asked Parke-Davis to contact Elliot
Luby, a psychiatrist at the Lafayette Clinic, who had
previously used phencyclidine (Sernyl) to induce the
same phenomena in normal volunteers and psychiatric
patients (Domino, 2010). The Parke-Davis researchers
were concerned that Luby would conclude that ketamine
was schizophrenomimetic, which would perhaps result
in the Parke-Davis executives and lawyers stopping its
development. It was a reasonable concern, as Luby earlier
documented that phencyclidine-induced states had
similarity to “schizophrenic syndrome” (Luby, Cohen,
Rosenbaum, Gottlieb, & Kelley, 1959). Consequently,
Parke-Davis insisted that their own psychiatrist observed
the subjects recovering from ketamine anesthesia. This
psychiatrist concluded the subjects had an emergence
reaction quite similar to diethyl ether (Domino, 2010).
Emergence delirium is not a new phenomenon
in clinical practice. Eckenhoff and colleagues (1961)
had reported the signs of “hyperexcitation” in patients
“emerging” from diethyl ether, phencyclidine, or
cyclopropane anesthesia. This phenomenon refers to
a clinical condition in which patients experience a
variety of “behavioral disturbances,” including crying,
disorientation, sobbing, and thrashing during early
emergence from anesthesia (Eckenhoff et al., 1961).
Emergence delirium (a.k.a. “emergence reaction,”
“emergence agitation” and “emergence excitation”)
is defined as the disturbance of a patient’s attention
to and awareness of the environment accompanied
by disorientation, hyperactive motor behavior, and
perceptual alterations immediate postanesthesia (Sikich
& Lerman, 2004).
Parke-Davis understandably selected the less
frightening name of “emergence phenomenon” rather than
“delirium,” and seems to have underreported the frequency
of this controversial side-effect. For many years, ParkeDavis reported on their ketamine (Ketalar) data sheet that
the frequency of emergence phenomena was only 12%.
This number was too low, however, and was eventually
dropped from their later data sheet (Parke-Davis Product
Information Sheet, 1999-2000). The actual percentage
reporting emergence phenomena after ketamine anesthesia
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is close to 40% in many studies (Abajian et al., 1973;
Hervey & Hustead, 1972; Khorramzadeh & Lofty, 1973;
Krestow, 1974; O’Neil, Winnie, Zadigian, & Collins,
1972; Overton, 1975; Sadove, Shulman, & Fevgold,
1971). One study even reported a 100% incidence range
of emergence phenomenon (Garfield, Garfield, Stone,
Hopkins, & Johns, 1972).
It was quickly discovered that “emergence
phenomena” may occur independently of anesthesia
and can be reliably generated by an administration of a
sub-anesthetic dose of ketamine. Collier reported that,
at one-sixth to one-tenth of the dose used for general
anesthesia, ketamine can create psychedelic experiences
with disconnection from surroundings, perception of
floating, becoming disembodied as a mind or soul, and
even dying and going to a different world (Collier, 1972).
He also noted that loss of reality contact appears more
pronounced than with other psychedelics. In addition,
Collier reported that dissociative experiences often
seemed so authentic that users were not sure whether
they had or had not actually become “disembodied.”
The discovery that ketamine is a powerful
psychedelic drug did not end its popularity as
an outstanding anesthetic agent. Instead, use of
benzodiazepines (the most frequently used are
midazolam, lorazepam, and diazepam) and increasingly
propofol have been utilized to control emergence
problems due to their strong amnestic and dreamsuppressing properties. In addition, the combined use
of ketamine and benzodiazepines or propofol has the
advantage of providing increased sedation and anxiolysis
(Cartwright & Pingel, 1984; Domino et al., 1984;
Dundee, 1990; Haas & Harper, 1992; Tobin, 1982; Toft
& Romer, 1987; White et al., 1982; White et al., 1988).
Ketamine as a Psychedelic Drug
he ketamine dissociative experience (emergence
phenomena) is, in fact, a non-ordinary state of
consciousness (NOSC) during which the individual’s
awareness and perception are dramatically changed
and radically refocused. This psychedelic experience is
often induced by intramuscular injections of ketamine
in doses that are typically used for dissociative sedation
and lasts from 45 minutes to one hour. The patient
completely loses contact with external reality and gets
involved in a profound psychedelic experience. The
ketamine-induced non-ordinary states of consciousness
may include (Collier, 1972; Jansen, 1989a, 1989b, 1997;
Khorramzadeh & Lofty, 1976; Kolp et al., 2006, 2007;
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Krupitsky et al., 1992; Krupitsky & Grinenko, 1996,
1997; Krupitsky & Kolp, 2007; Lilly, 1968; Moore &
Alltounian, 1978; Weil & Rosen, 1983):
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Feelings of leaving one’s body (i.e., out-of-body
experience)
Awareness of becoming a non-physical being
Emotionally intense visions (e.g., of deceased
relatives, “angels,” “spirits”)
Encounters with archetypal beings (e.g., Christ,
Buddha, Krishna)
Encounters with non-terrestrial beings (e.g.,
“space aliens”)
Visits to mythological realms of consciousness
Re-experiencing the birth process
Vivid dreams and memories of past or future
incarnations
Experience of psychological death and rebirth
of self (i.e., near-death experience)
Feelings of ego dissolution and loss of identity
Experience of reliving one’s life
Deep feelings of peace and joy
Sense of transcending normal time and space
Feelings of interconnectedness with all people
and nature
Feelings of cosmic unity with the Universe and
God
Sense of sacredness
Profound sense of ineffability of the experience
Intuitive belief that the experience is a source
of objective truth about the nature of “absolute
reality.”

John Lilly, an American neuroscientist,
psychiatrist, and “psychonaut” (explorer of his own
mind, often with the aid of substances), began a series
of self-experiments with psychedelic substances in the
early 1960s. Initially, he used LSD, which he sometimes
self-administered in a sensory isolation flotation tank
(Lilly, 1972). Circa 1971, Lilly started an exploration of
the use of ketamine by self-administering various doses
of ketamine via intramuscular injections, often using an
isolation tank to enhance its effects (Lilly, 1978).
Lilly documented a relationship between
dosage levels and the qualities of ketamine experiences
that he himself had. He reported that intramuscular
injections of ketamine at 25 mg did not cause visual
images, whereas over 30 mg it produced such images
when eyes are closed. At above 50 mg, visual images
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became stronger; however, in his case there was no
dissociation of the mind from the body. At above 75
mg, visual images significantly increased and feelings of
detachment of the mind from the body began. At above
100 mg, visual images became intense even when the
eyes were open, and feelings of complete dissociation of
the mind from the body were common. At above 150 mg,
the mind completely disconnected from the body and
feelings of total dissolution of ego were common. The
doses above 300 mg produced unconsciousness (Lilly,
1978). However, like many long-term ketamine users,
Lilly developed a notable tolerance to ketamine over
the years, and thus his own dose-response relationships
changed (summarized in Jansen, 2001). Lilly proposed
utilizing ketamine as a psychotherapeutic agent by using
ketamine-induced non-ordinary states of consciousness
for reprogramming the interface of brain-mind, and also
described ketamine’s antidepressant effects (Lilly, 1972).
Ketamine-Induced Non-Ordinary
States of Consciousness
etamine induces at least four distinct NOSCs that
depend on at least three major factors (as is the case
with all other classical hallucinogenic substances): the

K

dose of ketamine, the physical “setting” of the ketamine
administration, and the mindset (often just referred to as
“set”) of the person prior to the ketamine administration
(see Table 1). These different states of consciousness may be
partly distinguished by: a) the degree of a dissociation of the
mind from the body, and b) the degree of ego dissolution.
			 In considering the effects of substances on a
person, amongst other factors it is necessary to consider
the dose taken, how it is taken, and the speed at which it is
taken, the size and gender of the person, other substances
taken (either before, at the same time or afterwards), the
tolerance of the individual, and the set and setting. The
term set includes personality, past experiences, mental
health, mood, motivations, intelligence, imagination,
attitudes, what is going on in his or her life, and his or her
expectations. The term setting refers to the conditions
of use, including the physical, social, and emotional
environment, including the other people present.
The first state is an empathogenic (or “generating
a state of empathy” or “heart-opening”) experience. The
term “empathogenic” was proposed in the early 1980s
by Ralph Metzner, and is generated in response to an
injection of a low sub-psychedelic dose of ketamine,

Table 1. Ketamine-induced non-ordinary states of consciousness
State			Features				Typical Ketamine Dose

Duration

Empathogenic Experience
			
			

Awareness of body; comfort and relaxation;
reduced ego defenses; empathy, compassion,
and warmth; love and peace; euphoria; mind is
dreamy with non-specific colorful visual effects

Low sub-psychedelic dose similar to
45-60 mins
that used for anxiolysis and/or 			
analgesia (0.25 mg/kg – 0.5 mg/kg IM,
or 25 – 50 mg IM)

Out-of-Body Experience
(OBE)
			

Complete separation from one’s body; 		
significantly diminished ego defenses;
visits to mythological realms of consciousness;
encounters with non-terrestial beings;
emotionally intense visions (e.g., deceased
relatives, spirits); vivid dreams of past and future
incarnations; re-experiencing the birth process

Medium psychedelic dose such as
that used for mild conscious
dissociative sedation (0.75 mg/kg –
1.5 mg/kg IM, or 75 mg – 125 mg IM)

45-60 mins

Departure from one’s body; complete ego
dissolution/loss of identity; experienced physical
(body) and psychological (mind) death;
experience being a single point of consciousness
simply aware of itself; reliving one’s life;
aware of how actions have affected others,
with moral judgment of self

High psychedelic dose such as that
used for moderate to severe
conscious dissociative sedation
(2.0 mg/kg – 3.0 mg/kg IM, or
150 – 250 mg IM)

45-60 mins

Rare in low doses (0.25 mg/kg –
0.5 mg/kg IM, or 25 – 50 mg IM),
more common in high psychedelic   
doses (2.0 mg/kg – 3.0 mg/kg IM,
or 150 – 200 mg IM)

45-60 mins

			
			
Near-Death Experience
(NDE)
			
			
			
Ego-Dissolving 		
Transcendental Experience
(EDT)
			

Ecstatic state of the dissolution of boundaries
between the self and external reality; complete
dissolution of one’s body and self (soul);
transcending normal mass/time/space 		
continuum; collective consciousness; unity with
			Nature/Universe; sacredness
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the type of dose that may be used for anxiolysis and/or
analgesia (0.25 mg/kg – 0.5 mg/kg IM, or 25 mg – 50
mg IM). This state lasts from 45-50 minutes to 1-2 hours
and may be characterized by the following features:
•
•
•

•
•
•
•
•
•
•

The awareness of the body remains wellpreserved
The body feels very comfortable and relaxed
The ego functioning is wellmaintained;however, the ego defenses are
significantly lessened
The person experiences feelings of empathy and
compassion for themselves
The mind feels emotional warmth, well-being,
and joy
Strong feelings of love and peace are prevailing
Feelings of euphoria, pleasure and joy are
common
Feelings of ecstasy and enhanced sensuality are
frequent
The mind is dreamy with frequent non-specific
colorful visual effects
The person may feel they have forgiveness and
understanding of themselves and for those with
whom they have important relationships.

It is also entirely possible for these doses to produce
marked dysphoria and other unpleasant changes in
mental and physical state. This is far more likely to
happen if the set and setting are negative.
The empathogenic NOSC is like the state induced
by sub-psychedelic doses of classical hallucinogenic
substances (LSD, psilocybin, DMT, mescaline, etc.),
or regular doses of classical empathogenic substances
(MDA, MDMA, 2-CB, etc.). This state can be combined
with guided imagery or verbalized meditations and may
sometimes be utilized to resolve long-standing intrapsychic conflicts, to treat the aftereffects of trauma in
the victims of physical and sexual abuse or other assault,
to control the symptoms of post-traumatic stress disorder
(e.g., in soldiers), or to resolve interpersonal problems in
spousal and family relationships. Unlike the other three
NOSC, which are more intense and overpowering, an
empathogenic experience is more likely to leave the
patient with an ability to consciously recall this particular
non-ordinary state of consciousness.
The second NOSC is an “out-of-body experience”
(OBE), and may be induced in response to an injection
of a medium psychedelic dose of ketamine, which is in
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the range used for mild conscious dissociative sedation
(0.75 mg/kg – 1.5 mg/kg IM, or 75 mg – 125 mg IM).
This state lasts from 45 minutes to 1 hour and may be
characterized by the following features:
•
•

•
•
•
•
•
•
•

Feelings of complete separation from one’s body
The ego defenses are significantly diminished;
however, the rudimentary ego structure is still
preserved and the experiencer is well-aware of
the self
Awareness of becoming a non-corporeal being
Apparent visits to mythological realms of
consciousness
Apparent encounters with non-terrestrial
beings (e.g., “space aliens”)
Emotionally intense visions (e.g., deceased
relatives, “angels,” “spirits”)
Encounters with archetypal beings (e.g.,
Krishna, Buddha, Christ)
Vivid dreams and memories of past or future
incarnations
Re-experiencing the birth process.

This NOSC is similar to the state that can sometimes
be induced by medium doses of classical hallucinogenic
substances (LSD, psilocybin, mescaline, etc.), although
the visions are more realistic, well-defined, and
frequently get organized into a specific “story.” This type
of experience can bring to the conscious awareness a
plethora of unconscious material and may be utilized as
an adjunct to psychodynamic psychotherapy. This state
may sometimes be enhanced when combined with calm,
evocative music (e.g., classical, Trance, or New Age) to
assist with relaxation and immersion into the experience.
Unlike an empathogenic experience, OBE leaves the
person with only a partial ability to consciously recall
all details of this particular NOSC after the experience,
partly due to an avalanche of phantasmagoric visions
and sensory overload, and partly for physical reasons as
more extensive NMDA receptor blockade interferes with
memory formation (Collingridge, 1987; Jansen, 1990a,
1990b).
The third NOSC is a “near-death experience”
(NDE), which may be induced by an injection of a high
psychedelic dose of ketamine, in the range that may
be used for moderate to severe conscious dissociative
sedation (2.0 mg/kg – 3.0 mg/kg IM, or 150 – 250 mg
IM). This state lasts from 45 minutes to 1 hour and is
characterized by the following features:
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This NOSC is similar to the state that is sometimes
induced by high doses of classical hallucinogenic
substances (e.g., LSD, psilocybin, DMT, mescaline),
although the visions may be more intense, wellstructured, and liable to become organized into a
form of life review. Some research has found that
approximately 70% of NDEs are accompanied by
feelings of calm and peace, while about 30% of NDEs
are very frightening (Greyson, 1983; Greyson &
Stevenson, 1980). This NOSC type of experience can
sometimes bring enhanced insight into one’s deeds and
misdeeds, and may sometimes be very beneficial as an
adjunct to existential psychotherapy as well as to socalled “ego death/rebirth” psychotherapy (Krupitsky &
Grinenko, 1997; Kungurtsev, 1991). This state may also
be combined with non-associative, evocative music to
assist with an immersion into the experience. Similar to
the OBE, the NDE leaves the patient with only a partial
ability to consciously recall this particular NOSC on

the following day, although key features of the overall
experience may be surprisingly well-remembered
(i.e., surprising because ketamine’s action at NMDA
receptors and on neurotransmitters is likely to impede
short-term memory.)
Ketamine’s ability to replicate NDEs is
well-documented (Collier, 1972; Domino, Chodoff,
& Corssen, 1965; Ghoneim, Hinrichs, Mewaldt,
& Petersen, 1985; Grinspoon & Bakalar, 1979;
Kungurtsev, 1991; Lilly, 1968; Rumpf et al., 1969;
Siegel, 1978, 1980, 1981; Sputz, 1989; Stafford &
Golightly, 1967; White et al., 1982). One of our authors
(Jansen) analyzed similarities between ketamineinduced transpersonal experiences and NDEs in
a series of studies, concluding that 150-200 mg of
ketamine can reproduce all of the features commonly
associated with NDEs (Jansen, 1989a, 1989b, 1990a,
1990b, 1991, 1997, 2001). Three of this paper’s authors
(Jansen, Kolp, & Sylvester) had personal NDEs
from natural causes, as well as NDE-like ketamineinduced experiences, and can personally verify the
striking similarities between both phenomena (e.g.,
a compelling sense of being dead, sensations of
moving through a tunnel, one’s life review, visits of
non-physical realities, encounters with non-corporeal
entities, an experience of the void).
NDEs can be very transformative in some
people, and can induce positive changes in spiritual
development and worldview (Ring, 1980, 1984; Ring
& Valeriano, 1998). Ketamine-induced NDEs appear
to be equivalent to natural NDEs and may facilitate
stable recovery by accelerating patients’ psychospiritual growth and broadening their worldviews
(Kolp et al., 2007, 2009; Krupitsky & Grinenko, 1997;
Krupitsky & Kolp, 2007). In addition to bringing
an insight into one’s existential problems, the NDE
can also generate a spontaneous resolution of the
patient’s addictive illnesses, psychological problems,
and personality disorders. These experiences can also
generate a spontaneous spiritual conversion and a
dramatic improvement in moral character (Kolp et al.,
2007, 2009; Krupitsky & Grinenko, 1997; Krupitsky
& Kolp, 2007).
The fourth type of NOSC is perhaps the
most fascinating and sometimes the most potentially
beneficial ketamine-induced experience, as it is an egodissolving transcendental (EDT) experience (an ecstatic
state of the dissolution of boundaries between the self
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•
•
•
•
•

•
•
•

•
•

•

•
•
•

Feelings of complete departure from one’s body
Feelings of complete ego dissolution and loss of
identity
A strong belief of being physically dead
Experience of psychological death of the mind
(the self)
Feelings of becoming a single point of
consciousness (the Self, or a soul) that is simply
aware of itself with no other points of reference
Sensations of moving through a tunnel
Experience of reliving one’s entire life
Becoming aware that one is responsible for
every thought, word, and action of one’s life
prior to the NDE
Awareness of how others were affected by one’s
thoughts, words, and actions
Performing the moral judgment of the self
based on one’s own sense of right and wrong
holding one accountable for one’s thoughts,
words, and actions
Experience of visiting non-physical realities
(either paradisiacal or hellish realms of
consciousness) based on one’s own selfjudgment
Encounters with non-corporeal entities
Experience of visiting an eternal, featureless
void (nothingness)
Experience of psychological rebirth of the ego.

and external reality) which may be characterized by the
following features:
•
•
•
•

•
•
•
•
•
•
•
•

Feelings of complete dissolution of one’s body
Feelings of complete dissolution not only of ego
but also the self
Sense of transcending normal mass/space/time
continuum
Feelings of interconnectedness with all
people (or sense of experiencing collective
consciousness)
Feelings of cosmic unity with nature
Feelings of cosmic unity with the universe
Feelings of becoming a “Unified Field”
Feelings of becoming God, frequently
experienced as an ocean of brilliant white light
Deep feelings of love, peace, serenity, joy, and
bliss
Profound sense of sacredness of the experience
Profound sense of ineffability of the experience
Intuitive belief that the transcendental
experience is a source of objective truth about
the nature of absolute reality.

There are some indications that the EDT experience is
not always dose dependent and may occur even with a
low dose of ketamine (0.25 mg/kg – 0.5 mg/kg IM, or
25 – 50 mg IM), although it is more frequent with a
high psychedelic dose of ketamine (2.0 mg/kg – 3.0 mg/
kg IM, or 150 – 250 mg IM). The EDT experience may
last from 45 minutes to 1 hour and may be an excellent
adjunct to transpersonal psychotherapy.
Similar to the NDE, the EDT experiences
sometimes generate some resolution of the patient’s
addictive illnesses, psychological problems, and
personality disorders, including instances of spontaneous
healing from chronic psychosomatic illnesses,
particularly where these are dissociative/conversion in
type. In addition, there are some anecdotal accounts of
patients who had a spontaneous remission of some forms
of serious medical disease (Fenwick & Fenwick, 1995;
Grey, 1985; Morse & Perry, 1992; Ring & Valeriano,
1998; Roud, 1990). Like NDEs, EDT experiences have
the advantages of potentially rapidly accelerating patients’
psychospiritual growth, broadening their worldviews,
and possibly generating a spontaneous spiritual change
with an improvement in moral character (Kolp et al.,
2007, 2009; Krupitsky & Grinenko, 1997; Krupitsky &
Kolp, 2007).
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Psychedelic Psychotherapy
he acute psychological effects of ketamine can be
psychedelic in nature. There are many previous
studies on the effectiveness of psychedelic psychotherapy
(Grinspoon & Bakalar, 1979; Grof, 1980; Jansen, 1997,
2001; Khorramzadeh & Lofty, 1973, 1976; Kolp et al.,
2006, 2007, 2009; Krupitsky & Kolp, 2007; Krupitsky
et al., 1992, 1997, 2002; Kurland et al., 1971; Leary,
Metzner, & Alpert, 1964; Roquet, 1974; Strassman,
1995) suggesting that incorporating a psychedelic
experience into psychotherapy may have beneficial
effects in many ways, including:

T

•
•
•
•
•
•
•

Contributing to the cathartic process
Stabilizing positive psychological changes
Enhancing personal growth and self-awareness
Catalyzing insights into existential problems
Increasing creative activities
Broadening spiritual horizons
Harmonizing relationships with the world and
other people.

Although the ceremonial and therapeutic uses of
hallucinogenic drugs have been known worldwide for
millennia (Furst, 1972; Schultes & Hofmann, 1979),
scientific research of psychedelic-assisted psychotherapy
began more recently. Some of the experiments of
the great British chemist Sir Humphrey Davy, later
President of the Royal Society, with nitrous oxide at the
Pneumatic Institution at Bristol, in the late 18th and early
19th century, hinted at what was possible; unfortunately,
the opportunity was entirely missed, including the
opportunity to develop nitrous oxide as what would have
been the first anesthetic, with Sir Davy later dismissing
his experiments into the effects of nitrous oxide on the
mind as frivolous. Consequently, surgical operations
continued to cause terrible pain for at least another
100 years. The failure to see the opportunities was
partly cultural and has been related to the 19th century
cultural attitude to pain (Holmes, 2008). Cultural
attitudes, rather than issues genuinely related to science
and medicine, may currently play an important role in
greatly restricting the use of psychedelic psychotherapy
in contemporary society, but there are some signs of a
thaw.
The Italian psychoanalyst Baroni (1931) started
using a mixture of mescaline and Datura stramonium as
an aid in psychoanalytical psychotherapy in the 1920s,
and the work of Meduna (1950) with carbon dioxide
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is also worthy of note. However, psychedelic research
largely began in the 1950s, after Sandoz Laboratories
distributed lysergic acid diethylamide (LSD) and
psilocybin to all researchers interested in hallucinogenassisted therapy. Since then, the scientific investigation
into psychotherapeutic uses of psychedelic drugs has
been conducted in many countries and resulted in the
release of dozens of books and more than 1000 peerreviewed clinical papers reporting the use of psychedelic
substances administered to more than 40,000 subjects
(Dyck, 2005; Grinspoon & Bakalar, 1979; Passie, 1997).
Numerous clinical research studies of the subjects treated
with psychedelic compounds, performed from the late
1950s through the present time, repeatedly demonstrated
sometimes impressive treatment outcomes (e.g., Grob,
1998, 2002; Grof, 1980; Grinspoon & Bakalar, 1979;
Kolp et al., 2006, 2007, 2009; Krupitsky & Kolp, 2007;
Pahnke, 1968, 1969; Pahnke, Kurland, Goodman, &
Richards, 1969; Pahnke, Kurland, Unger, Savage, &
Grof, 1970; Pahnke, Kurland, Unger, Savage, Wolf, &
Goodman, 1970; Pahnke, McCabe, Olsson, Unger, &
Kurland, 1969; Richards, 1979/1980; Richards, Grof,
Goodman, & Kurland, 1972; Richards et al., 1979;
Richards, Rhead, DiLeo, Yensen, & Kurland, 1977;
Walsh & Grob, 2005; Watts, 1973; Yensen & Dryer,
1993/1994).
Hallucinogen-assisted psychotherapy evolved into
three major methodologies: hypnodelic psychotherapy,
psycholytic (“mind-loosening”) psychotherapy, and psychedelic (“mind-manifesting”) psychotherapy. Hypnodelic
psychotherapy has its goal as being to maximize the
power of hypnotic suggestion by combining it with the
low (sub-psychedelic) doses of hallucinogenic substances
in order to lower ego defenses without actually creating
a visionary experience (Grof, 1980). Hypnodelic
psychotherapy goes back to the nineteenth century, when
ether, nitrous oxide, and chloroform were used to induce
and deepen hypnotic states (e.g., Schrenck-Notzing,
1891). Later on, a procedure called “narcoanalysis” was
developed to use an amphetamine/barbiturate-induced
state of excitation/sedation to recall repressed conflicts
(Horsley, 1943). Its use in the treatment of “traumatic
combat neuroses” (one of the former names for posttraumatic stress disorder) attained some importance
(Grinker & Spiegel, 1945).
Psycholytic therapy (a.k.a “psycholysis”) involves
the use of medium doses of psychedelic drugs that create
a powerful mind-altering experience without dissolution

of ego functioning (Eisner, 1997; Eisner & Cohen, 1958;
Leuner, 1967). This technique was regularly practiced
in numerous European treatment centers during the
1950s and 1960s. In 1954 Sandison and Spencer
reported “abreactive memory actualizations” leading to
a remarkable progress of “neurotic” patients treated with
LSD (Sandison & Spencer, 1954). Around the same
time Leuner (1959) developed a day-dream technique
in psychotherapy that became established through the
present time as “guided affective imagery” (Leuner,
1977, 1984). He documented that treatment with low
doses of hallucinogens predictably generated regression
and catharsis experiences in his psychotherapy patients
(Leuner, 1959, 1971, 1977, 1984).
The earlier investigators reported that
psycholytic psychotherapy (or psycholysis) presented
to psychotherapists unique opportunities to overcome
rigid defense mechanisms in treatment-resistant patients
(Arendsen, 1963; Leuner, 1971; Mascher, 1967). Other
reported advantages of psycholysis, in addition to the
amplification of psychotherapeutic process, were its
capacity to increase the effectiveness of treatment and
to shorten the length of psychotherapy to half of the
typical time (Arendsen-Hein, 1963; Leuner, 1971, 1977,
1984; Mascher, 1967).
Psychedelic therapy involves the use of higher
doses of hallucinogenic drugs, with the aim of inducing
ego-dissolving transpersonal (e.g., transcendental,
mystical, spiritual) peak experiences (Grinspoon
& Bakalar, 1979; Grob, 1998, 2002; Grof, 1978,
1980, 1986; Grof & Halifax, 1976; Grof, Goodman,
Richards, & Kurland, 1973; Pahnke, 1968; Pahnke
et al., 1969, 1970; Richards et al., 1972, 1977, 1979;
Walsh & Grob, 2005; Watts, 1973; Yensen & Dryer,
1993/1994). This method was initially developed by
Hoffer and Osmond in the United States (Hoffer,
1967). In 1950, they observed that many alcoholic
patients developed a spontaneous remission after the
frightening experiences of a delirium tremens (Hoffer,
1967). Subsequently, they resolved to induce a facsimile
of delirium tremens with high doses of LSD, in order
to generate abstinence in alcoholic patients. To their
surprise, those patients who had positive experiences,
such as religious, spiritual, or mystical experiences,
had even longer lasting therapeutic effects (Hoffer,
1967). Following their original experiments, Osmond
and Hoffer developed the technique of psychedelic
psychotherapy based on the induction of mystical
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experiences. They used a quasi-religious preparation,
high doses of LSD, specific surroundings, and evocative
music to attempt to induce a transformative mystical
state of consciousness (Hoffer, 1967).
Pahnke (1962) conducted a double-blind
experiment and scientifically documented that the
induction of mystical experiences (“Unio mystica”) can
generate rapid acceleration of psychospiritual growth.
His work was further replicated by Leary, Litwin, and
Metzner (1963) who came to the same conclusion.
The reports based on ethnographic observations
of the ritual administration of certain hallucinogenic
plants are also relevant. La Barre (1989) and Andritzky
(1989) documented dramatic positive personality
changes in individuals with alcoholism who participated
in indigenous shamanic ceremonies (Peyote cult and
Brazilian Ayahuasca religion).
During the 1960s and 1970s, the psychedelic
technique was extensively studied and further optimized
at the NIMH Psychiatric Research Center and Spring
Grove Hospital (Grof, 1975, 1978; Pahnke et al., 1970;
Richards et al., 1977; Yensen & Dryer, 1993/1994).
Both hypnodelic and psycholytic psychotherapies
were usually conducted repeatedly at intervals of 1-4
weeks, between 10 and 50 psychotherapeutic sessions,
in combination with hypnotic, psychoanalytical, or
psychodynamic psychotherapy (Eisner, 1997; Eisner &
Cohen, 1958; Grof, 2001; Leuner, 1967). Psychedelic
psychotherapy generally included one to three sessions
with a psychedelic agent, greatly depended on set and
setting, and was generally administered as a part of
humanistic, existential, or transpersonal psychotherapy
(Grinspoon & Bakalar, 1979; Grob, 1998, 2002; Grof,
1978, 1980, 1986; Grof & Halifax, 1976; Grof et al.,
1973; Kolp et al., 2006, 2007, 2009; Krupitsky & Kolp,
2007; Pahnke, 1968, 1969, 1970; Richards et al., 1972,
1977, 1979; Walsh & Grob, 2005; Watts, 1973; Yensen
& Dryer, 1993/1994).
Hallucinogen-assisted psychotherapy has
been used for the treatment of people with a variety of
psychological problems, including alcoholism and other
addictive illnesses, anxiety and mood disorders, autism,
psychosomatic diseases, criminal recidivism, and end-oflife issues, to name a few. The previous studies asserted
that the most powerful results from treatment were
induced by transpersonal (e.g., transcendental, mystical,
spiritual, or religious) peak experiences (Pahnke, 1968,
1969; Pahnke, Kurland, Goodman, & Richards, 1969;

98

International Journal of Transpersonal Studies

Pahnke, McCabe, Olsson, Unger, & Kurland, 1969;
Pahnke, Kurland, Unger, Savage, & Grof, 1970; Pahnke
et al., 1970). This mystical peak experience (an egodissolving non-ordinary state of consciousness) induced
by psychedelic substances can be in turn used to accelerate
and enrich the course of psychotherapy. Depending on
the therapist’s school of thought, the ego-dissolving
transcendental experience can be used as an adjunct to
behavioral/cognitive, psychoanalytical/psychodynamic,
humanistic/existential, or transpersonal psychotherapy.
Each school of psychotherapy has its advantages and
shortcomings. However, it seems that psychedelicinduced non-ordinary states of consciousness may be
successfully used as an adjunct for several major schools
of psychotherapy. It is thus understandable that, since
the early 1970s through to the present time, a number
of international psychiatric investigators have utilized
ketamine-induced non-ordinary states of consciousness
for psychotherapeutic treatment of various psychological
problems, mental diseases, chemical dependencies,
psychosomatic illnesses and personality disorders.
History of
Ketamine Psychedelic Psychotherapy
oquet was the first clinician to publish results from
using ketamine for psychedelic psychotherapy,
which occurred in Mexico (Roquet, 1975; Roquet &
Favreau, 1981; Roquet, Favreau, Ocana, & Velasco,
1971). He combined traditional psychoanalytical
techniques with the shamanic healing practices of
indigenous Mexican Indian ceremonies and created a
new approach to psychedelic psychotherapy that he called
“psychosynthesis” (not the psychosynthesis developed
by Robertos Assagioli, 1965). Roquet utilized ketamine
1.5 mg/kg (or approximately 125 mg IM) and treated
primarily neurotic patients, although he described some
success with character disorders and selected psychotic
patients (Roquet, 1975; Roquet & Favreau, 1981;
Roquet et al., 1971; Yensen, 1973, 1985). His therapeutic
regimen also incorporated other psychedelic substances,
such as LSD, mescaline, and psilocybin. Roquet used
ketamine (and other psychedelic substances) in a group
setting between 1969 and 1974 and applied his technique
of psychosynthesis to approximately 150 patients
(Yensen, 1985). He reported positive outcomes in 85%
of his patients (Roquet, 1975; Roquet & Favreau, 1981;
Yensen, 1985).
Roquet described four levels of possible
experiences with ketamine (as well as with all other
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psychedelic compounds he utilized). The first and
most superficial level is a level of minor perceptual
distortions. The second level is a level of wish
fulfillment and fantasy (as the patient merely runs
from problems with pleasant fantasies). Although
patients can experience certain mystical states on this
level, the experience usually does not yield true insight
and results in only minimum reorganization of the
personality. The third level is the level of existential
anxiety and is often characterized by experiences of
psychological death and rebirth. This level is frequently
accompanied by the feeling of intense abreaction
with catharsis afterward. The fourth level is the most
intense, when the personality disappears completely,
all previous points of reference are lost, and profound
reorganization occurs. At this level, true life-altering
experiences of a mystical nature can take place. Roquet
regarded this level as essential to successful therapy
and aimed to synthesize a healthy personality through
the integrative qualities of this experience (Roquet,
1975; Roquet & Favreau, 1981; Yensen, 1973).
In Argentina, Fontana (1974) employed ketamine
as an adjunct to psychotherapy for depression to facilitate
regression to prenatal levels combining disintegration
and death followed by progression to rebirth. He reported
that ketamine allows therapists to introduce themselves
into, and to correct, primitive experience through the
relationship. Fontana emphasized the advantages of
ketamine as making it possible to reach deep levels
of regressions that had not been observed previously.
However, we could not find the specific dose of ketamine
he utilized, the type of psychotherapy he applied to his
clients, or the specific number of the patients he treated
with ketamine psychedelic psychotherapy.
In Iran, Khorramzadeh and Lofty (1973)
administered ketamine as an “abreactive agent” to patients
with various psychiatric illnesses (anxiety, depression,
phobias, obsessive-compulsive neurosis, conversion
reaction, hypochondriasis, and hysteria) and psychosomatic
disorders (tension headaches and ulcerative colitis). Subjects
were chosen from the inpatient population of a psychiatric
unit of a university hospital in southern Iran. A total of
100 patients (61 males and 39 females) were investigated,
ranging in age from 16 to 66. Patients with organic brain
syndrome and psychoses were excluded.
Ketamine was administered intravenously in 3
dose ranges in Khorramzadeh and Lofty’s (1973) work.
The first group (25 patients) received 0.2 – 0.3 mg/kg

body weight. Of the 25 subjects in this group, only
one was reported as having a minimal response and 24
showed no response. These 24 were then given a higher
dose of ketamine (0.4 – 0.6 mg/kg body weight) along
with 72 others. A total of 95 demonstrated the abreactive
response consisting of excitement, emotional discharge,
verbalization of conflict, and emergence phenomena.
Of the latter, all had facilitation of their psychotherapy
and symptom relief. Group 3 included only one failure
from the group 2 as well as 3 new patients. They received
0.7 – 1.0 mg ketamine/kg of body weight. According to
the authors, all of these patients showed the abreactive
response and had facilitation of their psychotherapy with
symptom relief. In total, 74 subjects had intense visionary
experiences; out of those, 51 patients recalled vividly
painful childhood events regarding the key figures in
that period. The complications were described as very
minimal and included apprehension (2 subjects), nausea
(3 subjects), and vomiting (2 subjects), which were treated
with perphenazine (5 mg IM) with positive response.
Khorramzadeh and Lofty’s (1973) subjects
were seen 6 months after the injection. Only 9 patients
were not doing well at this time, while ninety-one of
the patients were doing quite well. After one year, 88
patients were still being observed and all except two
were reported to be doing well (one had ulcerative colitis
and the other tension headaches). They both requested
another injection which was given and led to relief of
symptoms for an unspecified period of time. They
postulated that ketamine activated unconscious and
repressed memories, while it could temporarily transport
the patient back into childhood, reviving traumatic
events with intense emotional reaction. They also
concluded that ketamine’s cathartic effect was related to
its mind-expanding qualities and recommended the use
of this chemical as an abreactive agent.
Khorramzadeh and Lofty (1976) later
conducted another study to determine the types
of ketamine-induced emergence phenomena and
to discover any possible correlation between this
phenomena and the type of personality involved. They
used Eysenck’s Personality Inventory (EPI) to evaluate
the three dimensions of personality (Extraversion or E,
Neuroticism or N, and Psychoticism or P) in patients
who undertook ketamine anesthesia during surgery. A
total of 606 patients were given a Persian adaptation of
EPI the night before Ketamine anesthesia for operation.
The maximum score accepted as normal for E and N

Ketamine Psychedelic Psychotherapy

International Journal of Transpersonal Studies 99

was 11, and for P was 5. When E fell below 5, it was
considered an indication of Introversion. Out of 606
patients, 394, or 65%, showed no reaction. All of them
had normal scores. The remaining 212 patients, or 35%,
fell into the following seven groups, according to their
various scores:
•

•

•

•

•

•

•

Group E. Sixty-five patients (l0.7%) scored high in
E (over 14). They experienced pleasant dreams, and
some of them even felt they were in heaven among
angels. Later questioning showed that they were
all devoted Moslems. All of them expressed their
willingness to undergo the experience again.
Group N. Seventy patients (11.5%) had high
scores in N (over 14). They all felt dizzy and
related that to an experience of falls or rapid
circular movements. They were indifferent to
future use of the agent.
Group P. Only 15 patients (2.4%) had high
scores in P. They all reported body image
distortions, loss of control over their limbs, and
a sensation of a part of their body floating. In
some the reaction was such that it had to be
ended with perphenezine 5 mg IM. All refused
to go through the experience again.
Group NP. Fourteen patients (2.3%) scored
high both for N and P. They had the combined
experiences of groups N and P, making them
feel terrified and most apprehensive. They were
adamantly against future use of ketamine.
Group PE. Ten patients (1.6%) scored high both
in P and E. They screamed or laughed and had
increased motor activity and some used foul
language, while regaining consciousness. They
all stated that they had a good time and the
screaming was because of losing the pleasant
feeling. They were willing to undergo the
experience again.
Group NE. Eighteen patients (2.9%) had high
scores in N and E, and although they had the
feeling of falling or circling, it was not at all
unpleasant. One male patient stated that it was
like a funny orgasm without ejaculation. They
did not mind the future use of ketamine.
Group Low E. Twenty patients (3.3%) scored
5 or lower in E. They cried and used profanity
mostly directed at their close friends and
relatives. After regaining consciousness, 10
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of them had amnesia but the rest stated that
they knew they were using profanity but could
not control it. None wished to go through the
experience again.
Khorramzadeh and Lofty (1976) reported that
the EPI was found to be reliable in predicting the type of
emergence phenomena. The reported results apparently
showed that the majority of the patients (65%) did not
experience emergence phenomena at all (those with
normal scores). Of the remaining 35%, the majority had
either pleasant (those with high scores in E, EP, and NE)
or indifferent (those with high score in N) experiences.
Only 8% had unpleasant experiences (those with high
P and NP, and low E). This study supported that, in
emergency situations requiring keta
mine anesthesia,
the drug may be administered without undue concern
regarding the emergence phenomena, since only a small
minority of patients had very unpleasant side effects. The
study also documented that, in non-emergency situations,
a simple questionnaire may help the anesthesiologist to
select suitable candidates for ketamine induction.
Psychiatrist Stanislav Grof (1980) developed the
most comprehensive theory of psychedelic psychotherapy
from the transpersonal perspective. He wrote that
psychedelics facilitate therapeutic experiences of symbolic
death and rebirth of the ego, allowing clients to work
through deep traumatic fixations in their unconscious.
Grof designed a specific psychedelic psychotherapeutic
approach, which he applied successfully with more than
750 patients. Although Grof primarily used LSD in
his work, he acknowledged that ketamine holds great
promise due to its affinity with dynamic systems. He
reported that the psychoactive effect of ketamine is so
powerful that it can catapult patients beyond impasses
from previous LSD sessions to reach higher levels of
integration (Grof, 1980).
Last in this regard, we want to mention the
interesting recent work on DMT and spirituality, in the
United States by psychiatrist Rick Strassman (2000,
2014). We see this as very complementary to our interest
in ketamine.
Present Research on
Ketamine Psychedelic Psychotherapy
n Russia, one of us (Evgeny Krupitsky) conducted
the most comprehensive, rigorous scientific clinical
research on ketamine psychedelic psychotherapy to date
(Krupitsky & Grinenko, 1997; Krupitsky & Kolp, 2007;
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Krupitsky et al., 1990, 1992, 1999, 2002, 2007). He began
using ketamine as an agent for psychedelic psychotherapy
in 1985 in the former Soviet Union. His early exploration
of the use of ketamine as a psychotherapeutic agent
employed a behavioral psychotherapy, specifically an
aversive conditioning model for the treatment of alcohol
dependence that was customary in Russia before the
fall of the U.S.S.R. Krupitsky et al. (1992) combined
traditional behavioristic methods of aversive therapy
oriented towards creating negative associations between
the use of alcohol and undesirable physical effects
with earlier applications of psychedelic psychotherapy
for treatment of alcoholism that sought to change an
individual’s attitude towards the use of alcohol but
failed to imprint negative associations around the use
of alcohol (Smith, 1964; Smith & Seymour, 1985). He
created the affective contra-attribution (ACA) method
that combined both of these approaches.
Initially, Krupitsky induced an aversive
psychedelic experience by combining ketamine with
bemegride (an analeptic agent with strong anxiogenic
properties) in order to generate the frightening
emotive experiences and produce strong negative
emotions towards alcohol in the context of a terrifying
hallucinatory experience. This forms the basis of the
ACA method. These negative experiences are connected
with the use of alcohol and with the alcoholic’s life style.
Later on, Krupitsky learned that those subjects who
instead had an ecstatic transpersonal experience had
equally remarkable, if not greater, beneficial outcomes
and his work gradually shifted from a behavioral model
to an existential and eventually transpersonal paradigm
(Krupitsky & Grinenko, 1997).
Krupitsky initially used ketamine as an
alternative treatment for alcoholism only. His original
ketamine study demonstrated that KPP is highly
effective in the treatment of alcohol dependence. Of 111
patients who received KPP in the first study, 69.8% were
sober one year later, while only 24% in the control group
remained abstinent during the one-year follow-up period
(Krupitsky et al., 1992).
Krupitsky summarized his findings and
documented that his patients became less anxious and
depressed, more responsible and emotionally mature,
with increased ego strength and positive changes in selfconcept. His studies also showed that KPP brings about
profound positive changes in life values and purposes, in
attitudes to the different aspects of life and death, and

rapidly accelerates psychospiritual development. Patients
began to see other purposes, other values, other meaning
and pleasures in their lives, grew more self-confident and
balanced, more emotionally open and self-sufficient,
and more responsible for their lives and the lives of their
loved ones (Krupitsky & Grinenko, 1997).
Krupitsky and his team (1999) also examined
the effectiveness of KPP for the treatment of heroin
dependence. The team designed a double-blind
randomized clinical trial comparing the relative
effectiveness of a high psychedelic dose of ketamine (2.0
mg/kg IM) to a low non-hallucinogenic dose of ketamine
(0.2 mg/kg IM) for the psychotherapeutic treatment of
heroin addiction. The preliminary 6-month follow up
demonstrated that a hallucinogenic (psychedelic) dose of
ketamine was more effective than a non-hallucinogenic
(sub-psychedelic) dose. Two-year follow-up data
confirmed that the rate of abstinence in the high-dose
ketamine group was significantly higher than that in the
low-dose control group, while the corresponding rate of
relapse was lower (Krupitsky et al., 2002).
This comprehensive study with heroin addicts,
the first double-blind clinical trial of KPP conducted
entirely within the evidence-based medical paradigm,
clearly established that KPP significantly reduced the
craving for heroin, considerably decreased the levels of
anxiety and depression, markedly increased the level of
spiritual development, and, to a great extent, enhanced
understanding of the meaning and purpose of life.
Interestingly, many of the measured change variables
did not differ significantly between high and low dose
groups. This suggests that the psychotherapy common
to both groups played an important role in the observed
effects. This could also be the effect of set and setting
combined with a relatively low dose of ketamine. In
addition, the study demonstrated that KPP produced
few or no significant adverse reactions, and no subject
participating in the study became addicted to ketamine
(Krupitsky et al., 1999, 2002).
Krupitsky’s most recent work employed single
versus repeated sessions of ketamine-assisted psychotherapy in subjects with treatment-resistant heroin
dependence who do not respond well to the initial
treatment with KPP (Krupitsky et al., 2007). Fifty-nine
detoxified inpatients with heroin dependence received
one KPP session prior to their discharge from an
addiction treatment hospital, and were then randomized
into two treatment groups. Participants in the first group
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received two addiction counseling sessions followed by
two KPP sessions, with sessions scheduled on a monthly
interval (multiple KPP group). Participants in the second
group received two addiction counseling sessions on a
monthly interval, but no additional ketamine therapy
sessions (single KPP group). At one-year follow-up,
survival analysis demonstrated a significantly higher rate
of abstinence in the multiple KPP group. Thirteen out of
26 subjects (50%) in the multiple KPP group remained
abstinent, compared to 6 out of 27 subjects (22%) in the
single KPP group (p<0.05). Once again, no differences
between groups were found in anxiety, depression, the
severity of craving for heroin, or their understanding
of the meaning of their lives. The data from this study
provide some evidence that treatment-resistant patients
who did not experience a mystical state of consciousness
during the initial ketamine session may benefit from a
second or even a third ketamine session. It appears that
two or three repeated KPP sessions may work better and
provide a higher rate of abstinence in heroin addicts than
one KPP session, suggesting that increasing the number
of KPP sessions might increase the efficacy of treatment.
Krupitsky’s comprehensive clinical research of
ketamine psychedelic psychotherapy has clearly documented
that KPP is a safe and sometimes very effective treatment
for alcoholism and opioid dependencies. It also proved to
be efficacious in the treatment of stimulant dependence,
as well as a very effective modality for the treatment of
comorbid psychiatric conditions, such as posttraumatic
stress disorder, neurotic depression, anxiety disorders, and
avoidant personality disorders. In addition, his scientific
work demonstrated that KPP might be effective for the
treatment of phobic neurosis, obsessive-compulsive neurosis,
and histrionic personality disorder (Krupitsky & Grinenko,
1997; Krupitsky & Kolp, 2007; Krupitsky et al., 2002).
Many of Krupitsky’s patients developed a more
spiritual approach to life through their transpersonal
experiences. These encouraging clinical results occurred
because of positive changes in the life values and purposes,
relationships, and worldviews of these patients. They
showed a transformation of emotional attitudes, a decrease
in the level of inner discord, internal tension, discomfort,
and emotional isolation; improved self-assessment; and
a tendency to overcome the passive aspects of their
personalities. These significant changes, along with a
positive transformation of the patients’ system of life
values and meaning, as well as changes in their worldview,
created a positive attitude toward a sober life and supported
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patients’ ongoing stable sobriety (Krupitsky & Grinenko,
1997; Krupitsky & Kolp, 2007).
Unfortunately, changes in the regulations
governing ketamine research in Russia brought Krupitsky’s
research efforts to a halt. When Krupitsky began
working with ketamine psychedelic psychotherapy in
1985, psychedelics were not widely known in Russia and
ketamine was a Schedule III drug in that country. After the
collapse of the U.S.S.R., all drugs, including psychedelics,
became much more available in Russia, ketamine included.
Subsequently, ketamine abuse among Russian youth rapidly
escalated from the late 1990s. The Russian government
thus moved ketamine from Schedule III into Schedule II
in 2002. Ketamine remains available only for anesthesia
and conscious sedation at the present time in Russia. It
became unavailable for the treatment of addictive disorders
and psychiatric illnesses, and Krupitsky had to abandon his
innovative work with KPP.
Technique of
Ketamine Psychedelic Psychotherapy
rupitsky has developed a specific and comprehensive
course of KPP that comprises three main stages:
preparation, administration, and integration (Krupitsky
& Grinenko, 1997; Krupitsky & Kolp, 2007; Krupitsky
et al., 1990, 1992, 1999, 2002, 2007). In the preparation
stage, preliminary psychotherapy is carried out with
patients, who are told that the psychedelic session may
induce important insights concerning their personal
problems, their system of values, their notions of self
and the world around them, and the meaning of their
lives. Patients are educated that all of these insights may
lead to positive changes in their personalities, which will
be important for healing their underlying problems and
shifting to a sober lifestyle. At least five to ten hours of
psychotherapy are provided before the ketamine session
in order to establish the psychospiritual goal for the
transpersonal experience and prepare the subject for the
session. The therapist pays close attention to issues such
as the patient’s personal motives for treatment, goals for
a sober life, and ideas concerning the cause of the disease
and its consequences. The patient and therapist together
form an individually tailored “psychotherapeutic myth”
during this dialogue that creates an atmosphere of
confidence and mutual understanding during the first
stage of KPP. This then becomes the most important
therapeutic factor responsible for the psychological
content of the second stage of KPP (Krupitsky &
Grinenko, 1997; Krupitsky & Kolp, 2007).
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The second stage of this approach to KPP is
the induction of the transpersonal experience through
the administration of ketamine. Breakfast is omitted
on the morning of ketamine administration, and all
participants refrain from food and drink for at least eight
hours prior to this experience. Patients are told that they
will enter some unusual states of consciousness and are
instructed to surrender fully to the experience. After the
patient lies down in a comfortable supine position with
eyeshades, ketamine is injected intramuscularly, in doses
from 2.0 mg/kg to 2.5 mg/kg. The intramuscular route
is preferred because the onset is more gradual and the
psychedelic experience lasts longer. With an intravenous
psychedelic dose (from 0.7 mg/kg to 1.0 mg/kg), the
effect lasts only about 15 to 20 minutes, but with an
intramuscular injection, it lasts from 45 minutes to an
hour (Krupitsky & Grinenko, 1997; Krupitsky & Kolp,
2007).
With a background of specially chosen music,
generally free-floating non-associative classical or New Age,
the patient typically has a powerful non-ordinary state of
consciousness, frequently resembling a mystical experience.
After 45 minutes to an hour, the patient slowly comes
back from the experience. During the recovery period,
which takes from one to two hours, the patient begins to
feel ordinary reality returning. At this point in the session,
the patient usually begins to describe the experience and
some discussion and interpretation is begun with the
psychotherapist. After the session, the patient goes to rest.
The patient is asked to write down a detailed self-report
of the transpersonal ketamine experience that evening
(Krupitsky & Grinenko, 1997; Krupitsky & Kolp, 2007).
The third stage is the integration of the
ketamine-induced experience, which is carried out after
the ketamine session. It is generally done in a group
psychotherapy format, because the dynamic of the shared
group experience appears more powerful and therapeutic
than individual therapy alone. From three to five hours
of psychotherapy are provided after the ketamine session
to help subjects interpret and integrate their experiences
during the session into everyday life. With the aid of
the psychotherapist during the integration phase of
treatment, the patients discuss and interpret the personal
significance of the symbolic content of their ketamineinduced non-ordinary state of consciousness. This
discussion is directed toward helping the patients make
a correlation between their psychedelic experience and
their intra- and interpersonal problems. The therapist
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assists the patients in the psychological integration of
the spiritual transformation that can result from the
direct transpersonal experience. This uniquely profound
and powerful experience often helps patients to generate
fresh insights that enable them to integrate new, often
unexpected meanings, values, and attitudes about
the self and the world (Krupitsky & Grinenko, 1997;
Krupitsky & Kolp, 2007).
It should be explicitly pointed out that a
ketamine-induced psychedelic experience may have only
marginal and transitory beneficial effects in and of itself,
no beneficial effects at all, or may be harmful when
ketamine is used in uncontrolled settings recreationally.
It can sometimes lead to significant medical problems
and addiction (Jansen, 2000, 2001; Jansen & DarracotCanckovic 2001; Ricuarte, 2005). The therapeutic
relationship, as well as set and setting, are paramount to
the effectiveness of ketamine psychedelic psychotherapy.
In order for the KPP sessions to cause positive
transformative experiences, it is of central importance
to carefully prepare patients for the KPP session, to
attentively supervise them during the session, and
to provide extensive psychotherapy after the session
to facilitate the integration of the ketamine-induced
transpersonal experience and to help patients personally
accept insights gained during the KPP session (Krupitsky
& Grinenko, 1997; Krupitsky & Kolp, 2007).
Present Use of
Ketamine Psychedelic Psychotherapy
ne of us, Dr. Eli Kolp is a bi-cultural psychiatrist
and was originally trained in the former U.S.S.R. as
a public psychiatrist. After Kolp requested that the Soviet
authorities allow him to emigrate from the U.S.S.R., he
was instead sent to work as an addiction specialist in
the Moscow Alcohol and Drug Abuse Clinic #1, where
Kolp learned how difficult the treatment of alcoholism
in Russia could be. Even with the most intensive longterm treatment, which included multiple sessions of an
unpleasant aversive conditioning, more than 75% of
Russian alcoholics relapsed on alcohol within one year
after completion of treatment.
After Kolp immigrated to the United States in
1981, he successfully re-trained as a private psychiatrist
and began practicing general adult and geriatric
psychiatry. Circa 1990, Kolp returned to the treatment
of addictive illnesses, both in private and public sectors,
where he directed various outpatient, residential,
and inpatient programs specializing in the treatment
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of alcohol, drug, and/or food addiction. He quickly
learned that efforts to treat alcoholism in the American
population are costly and have a low rate of recovery, as
they do in Russia.
A previous meta-analysis of outcomes of treatment
for alcoholism (Nathan, 1986) showed that different
treatment methods did not appear to be associated
with significantly different long-term outcomes. It was
reported that treatment factors, including theoretical
orientation, content, locus, and intensity of treatment
revealed little or no difference in treatment outcome,
despite great differences in costs. Although abstinence
rates one year after treatment may reach 40% to 50% for
persons with good treatment prospects (well-motivated,
employed, sub-chronic alcoholics with a large network
of support and substantial personal resources treated at
private treatment facilities), typical abstinence rates for
poorly motivated, unemployed, chronic alcoholics with
a limited network of support and few personal resources
seen at public treatment facilities were 25% or less. Rates
of abstinence at and beyond the two-year mark are often
less than 50% of the rates of abstinence at the one-year
mark.
In the United States, Kolp, inspired by Krupitsky,
thus began working towards utilizing ketamine
psychedelic psychotherapy in 1994. His approach was
explicitly meant to replicate Krupitsky’s pioneering work
and to extend it into another cultural context, the United
States. With Krupitsky’s guidance (while Krupitsky was
working for one year with Krystal as a visiting scientist
in the Department of Psychiatry at Yale University),
Kolp designed a research protocol, entitled The KetamineAssisted Therapy of Alcoholism. The protocol was first
approved by the Safety Committee of the James A.
Haley Veterans Hospital in Tampa, Florida, and then
by the Research and Development Committee of the
Department of Veterans Affairs. It was further approved by
the Research Committee of the Department of Psychiatry
at the University of South Florida College of Medicine
and the Institutional Review Board of the University of
South Florida Health Science Center. Finally, by the end
of 1996, the protocol was approved by the FDA, which
issued to Kolp an Investigational New Drug permit.
Unfortunately, the implementation of the protocol never
materialized due to a lack of the institutional support and
an absence of research funds. The Department of Veterans
Affairs did not allow Kolp to use its facility and resources
for this purpose, apparently because of the controversial

nature of psychedelic psychotherapy at that point in time,
which was somewhat prior to the recent “thaw” which has
allowed some human work to be done with drugs such as
psilocybin and MDMA (e.g., Friedman, 2006; Griffiths,
Richards, Johnson, McCann, & Jesse, 2008; Griffiths,
Richards, McCann, & Jesse, 2006).
Kolp was also unable to obtain funding for the
study from multiple sources. It thus became necessary
to abandon the planned, formal research study. Instead,
Kolp employed ketamine psychedelic psychotherapy
(KPP) in his private psychiatric practice. During the
first several years (1994-1999), Kolp administered (KPP)
to more than 70 patients. The patients were males and
females, 21-64 years old, who identified alcohol as their
drug of choice and satisfied the diagnostic criteria for
alcohol dependence. Kolp followed all patients treated
with KPP for as long as they continued the aftercare
treatment, and he had individual and group sessions
with them on a regular basis, from once a month to once
every 3 months. In addition to being diagnosed with
alcoholism, the vast majority of Kolp’s patients (nearly
90%) had concurrent addictions (e.g., to caffeine,
sugar, nicotine, cannabis, benzodiazepines, opiates,
and amphetamines), and about half had coexisting
psychological problems (e.g., generalized anxiety
disorder, social phobias, primary insomnias, acute and
repeated stress disorders, pain disorder, panic disorder,
depressive disorder, posttraumatic stress disorder,
tension and migraine headaches, somatization disorder,
and chronic fatigue syndrome). As with Krupitsky’s
technique, Kolp’s treatment modality explicitly relied
on the transpersonal effects of ketamine to facilitate
psychotherapeutic change. Kolp experimented with
several different courses of treatment with KPP,
ranging from a time-limited individual treatment on
an outpatient basis to an intensive 1 to 3 week group
treatment in the framework of a residential program.
Kolp summarized his empirical clinical observations
on KPP effectiveness for treating alcoholism and other
coexisting disorders in his first report (Kolp et al.,
2006).
After gaining extensive experience with KPP
for the treatment of alcoholism, Kolp extended the
inclusion criteria for KPP and began accepting patients
with other drug dependencies and food addiction. Kolp
also started utilizing KPP for the treatment of end-of-life
anxiety in patients with terminal illnesses. He continued
utilizing group psychotherapy in a residential setting
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for treatment of addictive disorders and coexisting
psychological problems. In addition, Kolp continued
utilizing individual psychotherapy on an outpatient
basis for treatment of existential anxieties in terminally
ill people and selected patients with addictive disorders
who did not wish to participate in a residential treatment
program, or could not tolerate a group process.
During the second stage of his work with
KPP (2000-2006), Kolp treated approximately 100
patients with various addictive illnesses (primarily
alcoholism, opiate dependence, and food addiction),
concurrent psychological diseases (mainly anxiety and
mood disorder, acute and repeated stress disorders,
and psychosomatic disorders), coexisting personality
disorders, and existential anxieties related to the endof-life issues. Kolp documented his empirical findings
in a second report (Kolp et al., 2007). In addition,
Kolp collaborated with Krupitsky and both authors
published their combined experience and accumulated
data on clinical research and empirical observation of
the effectiveness of KPP (Kolp, Krupitsky, Friedman, &
Young, 2009; Krupitsky & Kolp, 2007).
During the third stage of his work with KPP
(2007 through the present), Kolp continued treating
patients with various addictive illnesses, concurrent
psychological diseases, and coexisting personality
disorders. He also started accepting for KPP selected
clients who had already resolved their addictions
and major psychological problems and were looking
for growth-oriented psychotherapy and lifestyle
optimization.
In addition, Kolp began treating patients
with chronic treatment-resistant depression (TRD),
which is presently defined as a failure to respond
to an adequate trial with two or three conventional
antidepressants. Interestingly, the vast majority of the
patients with TRD were not psychologically minded
and had no interest in KPP. Instead, they desired to
undertake only pharmacotherapy with a low subpsychedelic dose of ketamine. In total, during the past
7 years, Kolp administered KPP to approximately 150
“psychologically-minded” clients with drug and food
addictions, and ketamine pharmacotherapy to about 50
“pharmacologically-minded” patients with treatmentresistant chronic anxiety and/or depressive disorders.
Kolp also administered KPP in the same
3-stage format as was originally designed by Krupitsky:
preparation, administration, and integration. Kolp

always used a high psychedelic dose of ketamine (2.0
mg/kg – 2.5 mg/kg IM, or 150 – 200 mg IM) in order to
both avoid an OBE and to specifically induce the neardeath experience or, considered by Kolp as even more
desirable, the ego-dissolving transcendental experience.
Kolp disfavors an OBE for the same reasons that were
previously discussed by Roquet and colleagues (1971,
1975) and Yensen (1973): most of the time the OBE
simply represents the patient’s wish fulfillment and the
patient only runs from problems with pleasant fantasies.
Although the OBE may resemble certain mystical states,
the experience usually does not yield true insight and,
in fact, may even have a negative effect on the ego, as
illustrated by the following case study:
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C was a 52-year-old Caucasian female with a long
history of binge alcoholism. She reported a stable
childhood, with no history of physical or sexual
abuse. C was raised as a Roman Catholic. However,
she abandoned that denomination during her
late teens, continuing as a non-denominational
Christian.
C began using alcohol at age 16, started drinking
on a regular basis at age 18, and developed alcohol
binges at age 25. Her binges lasted from 3-4 days to
2 weeks, every several weeks, with a consumption
of nearly one liter of vodka a day during the binges.
She undertook more than 10 various rehabilitation
programs. However, she never had a stable remission
(her longest remission lasted 7 months, including
2 months in a rehabilitation program). C did not
wish to participate in a group residential program
and elected an individual outpatient treatment.
In addition, she did not follow strict preparatory
guidelines (a whole food plant based diet, optimal
hydration, daily meditation and exercise, limitation
of screen time, etc.). Moreover, she continued
using sugar, caffeine, and nicotine throughout the
preparatory stage. Although she received 150 mg
of ketamine IM, her ego remained well-preserved
and she did not experience EDT, or, at least, NDE.
Instead, she had an OBE that she described as
“paradisiacal”:
My mind left my body and I found myself in the
Heaven … flying high above the silver and gold
clouds … in the company of thousands of angels
who were there to guide and protect me. The music
was exceptionally lovely and we were ascending

Kolp quickly discovered that the OBE can
be fascinating and gratifying for the ego, but it can
sometimes have a rather low therapeutic potential outside
of a long-term psychodynamic psychotherapy that
requires repeated inductions of the OBE. Subsequently,
Kolp’s primary goal has been to induce the ego-dissolving
transcendental experience, or at least the near-death
experience, since both the NDE and EDT experiences
more frequently generate not only a complete resolution
of the patient’s addictive illnesses and coexisting
psychological problems, often after a single session, but
may also cause instances of spontaneous healing from
chronic psychosomatic illnesses (Fenwick & Fenwick,
1995; Grey, 1985; Kolp et al., 2007, 2009; Krupitsky
& Grinenko, 1997; Krupitsky & Kolp, 2007; Morse &
Perry, 1992; Ring, 1980, 1984; Ring & Valeriano, 1998;
Roud, 1990). In addition to its more specific healing
potentials, the NDE and the EDT experiences may
also rapidly accelerate patients’ psychospiritual growth,
broaden their worldviews, and generate a spontaneous
spiritual transformation with a dramatic improvement
of moral character (Kolp et al., 2007; Krupitsky &
Grinenko, 1997; Krupitsky & Kolp, 2007).
The primary factors that greatly influence the
likelihood of these desirable NDE and EDT experiences
are the dose of ketamine, the mindset of an individual
prior to the ketamine session, and the session’s setting.
To reiterate, the mindset is the mental state that a person

brings to the experience, such as thoughts, mood,
personality structure, expectations, and worldviews.
It is the most important part of KPP and basically
stands for a rigorous preparation for the ketamineinduced experience. The setting is also very important
and includes physical (the room’s atmosphere) and
social (feelings of the group’s participants towards one
another and toward therapist/therapists) components.
The social support network is particularly important
in the outcome of the ketamine-induced NOSC.
The group and/or a therapist are able to control and
guide the course of the experience, both consciously
and subconsciously. Anxiety prior to the experience or
a disagreeable environment may induce a frightening
experience. On the other hand, curiosity and a positive
attitude, together with a comfortable and safe place, are
more likely to generate a blissful experience.
In addition to set and setting, the novelty of
the psychedelic experience may be salient for successful
problem resolution. Psychedelics are a unique class
of drugs that produce intense effects unlike those of
other drugs, and one’s first “trip” can therefore be a
profound and life-changing experience (as common
wisdom says, “there is no second chance for the first
impression”). Consequently, for those with extensive
histories of psychedelic use, there is a diminished chance
that a ketamine experience will be all that unique and
transformative (“just another trip”), whereas for the
novice psychedelic user, given proper mindset and
setting, the experience can be profound.
Kolp believes that the most influential
component of a successful KPP (in addition to dose,
set, and setting) that can greatly increase the odds of
the optimal EDT experience is vigilant preparation prior
to the ketamine administration. Without a careful and
laborious preparation, only about half of the patients
may have an NDE (even with a dose of ketamine that
is set to cause a near-death experience) and only 1 out
of 20-25 patients may have an EDT experience. By
attentively preparing the patients for a ketamine-induced
experience through creating the spiritually-oriented
mindset (as well as carefully controlling the setting), the
likelihood of having an NDE becomes nearly universal.
Meanwhile, the likelihood of an EDT experience can be
increased from only 1 out of 20-25 patients to 3-4 out of
10 patients. Unfortunately, the EDT experience is very
elusive and there is no guarantee of the EDT occurrence
even with the most arduous preparation.
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higher and higher … eventually arriving into the
Garden of Eden. The angels showed me the beauty
of their home and then helped me to soar directly to
the throne of Jesus. His presence overwhelmed me
and I started crying and laughing at the same time.
I felt the Jesus’ unconditional love and understood
that all my sins were forgiven. He blessed me and I
promised Him to never ever touch another drink of
Vodka again. I then returned back into my body …
feeling joyful and full of bliss … and I knew–with
all my heart–that I got reformed forever.
She attended only one follow-up session and
proudly reported that she had rejoined her church
and started praying again on a daily basis. She insisted
that her encounter with Jesus completely healed her
from alcoholism and that she no longer needed to
participate in an AA 12-step recovery program. C
relapsed on alcohol 8 months later and committed
suicide soon after the end of her 2-week binge.

Whether the patient elects to participate in
a residential group program or outpatient individual
treatment, Kolp starts the preparatory period 6 weeks
prior to the induction of the ketamine experience.
During those 6 weeks, all patients participate in weekly
group psychotherapy (unless the patient does not want a
residential treatment, or cannot tolerate a group process;
in that case the patient is engaged in a weekly individual
psychotherapy). During the same 6 weeks, Kolp strongly
encourages all patients to prepare the body and mind
through partial fasting following a whole food plant based
(WFPB) diet, optimal hydration, de-stressing through
daily meditation, contemplation on the nature of the Self
and God, limitation of “screen” time, and daily exercise.
Kolp further suggests de-toxifying the body from all
sedatives (such as sugar, alcohol, benzodiazepines, and
opiates) due to their tendency to dull the mind and all
psychostimulants (such as caffeine, nicotine, ephedrine,
amphetamines) due to their tendency to aggrandize the
ego.
In the experience of Kolp, fasting is a key aspect
of the more acute preparatory process. The reasons why
this is of assistance to the outcome remain speculative,
but fasting has long been a part of the spiritual quest
in many cultures and religions because it seemed to
weaken the ties of the physical body to the material
realm. Fasting can be total, abstaining from all food and
beverages apart from water, or it can be partial. Kolp
never asks patients to undergo a total fast. However, he
highly recommends a partial fast and suggests abstaining
prior to the ketamine session from highly refined simple
carbohydrates (all sugary drinks such as soda pop and
fruit juices, chocolate, doughnuts, cookies, cake, candy,
etc.), highly processed complex carbohydrates (white
bread, rolls, pasta, white rice, French fries, etc.), dairy
products (milk, yogurt, sour cream, butter, cheese, ice
cream, etc.), fatty “rich” foods (steak, bacon, salami,
pastrami, hamburgers, cheeseburgers, etc.) and “junk”
foods (chips, pretzels, crackers, pizza, etc.). Participants
are encouraged to follow the WFPB diet, getting the
majority of calories from vegetables, with some calories
coming from certain whole grains, legumes, fruits, and
nuts. During the fasting period, optimal hydration is
strongly recommended by drinking one glass of water
(no carbonated, caffeinated, or sugary drinks of any
kind) every 2-3 hours during wakeful time.
To calm and prepare the mind, Kolp
recommends taking a time out for daily meditation or

mindfulness sessions. Ideally, participants would take
twenty to thirty minutes each day for this practice.
However, even ten to fifteen minutes daily is beneficial.
Kolp also recommends spending fifteen to twenty
minutes every day contemplating on the nature of the
Self and the nature of whatever the person understands
by the word “God” or the connectivity between the Self
and the rest of the Universe, or a Higher Power as in
the 12-step programs. Many participants find it helpful
to keep a journal during this time to document their
progress, including any regressions, in order to stay on
track during this phase.
In addition, Kolp strongly advises de-stressing
the mind by limiting “screen” time beyond that which is
required for each individual participant’s employment.
Recreational screen time should be limited to less than
two hours daily. Screen time includes, but is not limited
to, computer use, watching television, playing video
games, watching movies, and using smartphones.
Exercise is recommended at least five days a
week for a period of forty-five to sixty minutes at a time.
Kolp recommends low impact isotonic exercises such as
deep stretching or yoga; however, any type of exercise is
beneficial.
Although the preparatory guidelines may seem
strict, this conscious preparation of the body, mind,
and spirit prior to the administration of ketamine is
seen by Kolp as increasing the likelihood of having
either a classic NDE or distinct EDT experience.
In Kolp’s experience, after a detailed, vigilant, and
focused preparation, almost 50% of participants have
a classical NDE and nearly 35% participants have a
highly desirable EDT experience. Unfortunately, even
with the most arduous preparation, approximately
15% of participants still have a standard OBE. Most
of them are the patients who had a very high tolerance
to sedatives (e.g., sugar, alcohol, benzodiazepines,
barbiturates, and opiates), severe control issues (they
are simply unable or unwilling to surrender to the
existential or transpersonal experience), persistent
difficulties in maintaining long-term interpersonal
relationships, and those with dogmatic beliefs in an
authoritative or critical God.
After 6 weeks of an outpatient preparation and
detoxification as well as 6 weekly psychotherapy sessions,
the patients are placed in a structured residential setting
for the second stage of treatment—the administration of
ketamine-induced non-ordinary states of consciousness.
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The length of a residential component varies from 1
week (growth-oriented program) to 3 weeks (addiction
rehabilitation program). The one-week growth-oriented
residential program offers 30 hours of psychoeducational
and encounter groups, existential and transpersonal
group psychotherapies, and interactive classes and
didactic lectures. The three-week rehabilitation program
for the treatment of food and drug addiction provides
the same 30 hours of analogous psychoeducational and
encounter groups, existential and transpersonal group
psychotherapies, and interactive classes and didactic
lectures. In addition, it provides another 60 hours of
various life skills training such as communication skills,
problem solving skills, relapse prevention, relationship
skills, anger management, and decision-making, as
well as training in optimal lifestyle and advising health
issues, nutrition education with food purchase and
preparation, non-verbal therapies, such as art therapy
and music therapy, in order to provide the patients with
alternative means of self-expression, problem resolution,
and motivational enhancement. Those patients who opt
out of a residential component of a treatment program
receive the administration of ketamine in an outpatient
setting, without the benefits of an intense group process
of a residential program.
Whether ketamine administration is performed
in an outpatient office, or in a residential center, Kolp
recommends both settings have comfortable, scenically
pleasant, home-like atmospheres. Breakfast is omitted
on the morning of ketamine administration, and all
participants refrain from food and drink from midnight
through the ketamine-induced experience. The ketamine
solution is administered via a brief intramuscular
injection, rather than an intravenous administration
requiring the use of an IV line, adding to the comfort
of each patient. After the injection, the patient wears
eyeshades, is instructed to fully surrender to the ketamineinduced experience, and beautiful, evocative music starts
playing to assist with relaxation and immersion into the
experience.
The NOSC lasts from 45 minutes to an hour
under these conditions and then the patient slowly comes
back from the experience. During the recovery period,
which takes from one to two hours, the background
composition changes from a free-floating non-associative
music to an inspirational guided imagery meditation to
affirm the patient’s sought after transformation. When
patients returns to an ordinary state of consciousness,

they are asked to describe the experience, and some
limited discussion and interpretation is begun with the
psychotherapist. After the session, the patient goes to
rest and is asked to write down a detailed self-report of
the ketamine-induced transpersonal experience during
the second part of the day.
The integration of a ketamine-induced experience
starts on the evening after the ketamine session and
continues throughout the rest of the residential program.
After the end of a residential component of the treatment,
all patients continue weekly group psychotherapy
sessions on an outpatient basis for 3 additional weeks.
The patients who elect to participate in an outpatient
individual treatment also receive 3 weekly individual
psychotherapy sessions during the integration part of the
treatment. Afterward, Kolp provides follow-ups every 6
months for all patients treated with KPP for as long as
they continue to participate in aftercare.
With these in depth, challenging preparatory
and aftercare guidelines, Kolp was able to increase the
effectiveness of KPP from 70% reported by Krupitsky
(1992, 1997) to approximately 85% previously reported
by Roquet (1975) and Yensen (1985). So far, the longest
observed remission has been for 12 years (the patient
undertook a 3-week residential treatment program in
2002), as illustrated by the following case study:
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B was a 47-year-old Eurasian male who identified
himself as a food addict. He reported no childhood
trauma and described his nuclear family as very
loving and supportive. B was raised as a Methodist,
but changed his religious identification to a nondenominational Christian during his late teens and
eventually began identifying himself as “spiritual
but not religious” during his early 30s. He described
himself as a “steak and potato man” and was proud
of himself for never having a dessert. B had 6 feet 4
inches height and 220 pounds weight by age 18 and
remained very fit throughout his mid-20s due to a
very strenuous athletic involvement (a football player
in high school and 6 years of active duty service in
the Marine Corps). After an honorable discharge
from the armed forces at the age of 26, he became
employed as a manager of a fast food restaurant.
B described himself as a compulsive overeater,
who never attempted to compensate for his bingeing
with purging behaviors such as fasting, laxative use,
or vomiting. He did exercise a good deal through his

early 30s. However, he eventually stopped working
out and developed a sedentary lifestyle. In addition,
he became engaged in “grazing” behavior and started
picking at food throughout the day.
B’s food preference was for fats and flour
products, which he consumed three times a day, in
addition to snacking between his major meals. His
tolerance slowly increased and by his late 30s, his
typical breakfast consisted of one 8-ounce sirloin
steak, two big baked potatoes with sour cream, 4
scrambled eggs, a couple of sausages or 2 slices of
ham, and a half dozen biscuits with butter. His
lunch and dinner were equally impressive, always
including large amounts of meats, bread, and
butter. In addition, B had 3-4 self-made sandwiches
between his main meals, which he prepared from a
slice of ham or bologna meat, a slice of cheese, and
2 slices of white bread with butter. Once a month
he treated himself with a 30-ounce strip sirloin at
a steak house. B was a participant in an April 2000
survey, who would not give up meat for a week even
if he were paid a thousand dollars to do so.
By the age of 40, B’s weight reached 300 pounds.
He was already diagnosed with hypertension, type
II diabetes, hyperlipidemia, osteoarthritis, and sleep
apnea. He had to take eight medications a day and
his primary physician repeatedly warned him that
he was a few years away from a stroke or a heart
attack. At that point B started taking some action
and began dieting, but always unsuccessfully. He
would stay on a diet of the season for a few weeks and
sometimes drop several pounds in weight. However,
each time he resumed his compulsive overeating.
B joined Overeaters Anonymous (a 12-step
recovery program based on the principles of Alcoholics
Anonymous, which is also known as The Fellowship)
at age of 42, but left the program after a year (“too
much praying, but no spiritual awakening”). He also
briefly tried Food Addicts in Recovery Anonymous
(an alternative 12-step based program) and had no
problems with completely abstaining from sugar,
but could not abstain from the flour products
longer than several weeks. In addition, he resented
weighing and measuring all his meals and could not
abstain from snacking between meals. B undertook
a sleeve gastrectomy at age of 44, which helped him
to decrease his weight to 250 pounds. However, he
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managed to “re-feed” himself within 2 years after the
surgery. By the time he applied for treatment with
KPP his weight was 310 pounds.
B was willing to stop eating meat and dairy
products for 6 weeks prior to a ketamine session
and agreed to abstain from highly refined and/
or highly processed food for the same period of
time. He reported severe cravings for fats and flour
during the first 3 weeks. However, he was able to
remain abstinent from the prohibited items. B
actively participated in all groups, meditated twice
a day, and started walking for 30 minutes every
other day. Unbeknown to his therapist and the
group, B sneaked out of the residential facility the
evening prior to the administration of ketamine in
order to have his “last supper,” a veal parmigiana
dish. The following morning B received 250 mg of
ketamine IM and had a very frightening NDE that
he described as “hellish”:
I got out of the body and initially rejoiced the
freedom of leaving my fat and sick body. Within a
minute or two though my mind started dissipating
and it scared me very much. I remember thinking:
I am really dying … it is the end of my life … oh,
no, no … please make it stop. The mind completely
gone and all that remained was a soul … silent,
sad and lonely … rapidly falling into the abyss
of nothingness. At some point the movement ...
stopped and the soul became motionless in the
middle of the void. All of the sudden, my entire
life began getting replayed and the soul was
despondently observing my Earthly life of a glutton
… a hungry sponge devouring countless living
beings out of a lust for taste. The feeling of sorrow
became resilient and the last conscious awareness
was terrifying—if the Hell and the Heaven do, in
fact, exist, the soul definitely belongs to the Hell.
As soon as my soul came to this conclusion,
it got immediately sucked deep into an infinite
ocean of unconditional sorrow and became that
veal calf … taking away from the mother …
suspended in a stall … restricted in movements …
without seeing a sky and the trees … sensing that
something is terribly wrong … that it is not how
life is supposed to be lived … tormented and very
miserable … finally going through a cruelty of a
slaughterhouse … hanged upside down … skinned
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Although the above case is rather exceptional, the vast
majority of the patients treated with KPP do develop
a stable remission, lasting from 2-3 to 5-7 years and
longer. Kolp, like Krupitsky before him, has repeatedly
observed a dramatic improvement in patients’ overall
bio-psycho-socio-spiritual functioning, including rapid
optimization of a personal lifestyle, decreased levels of
inner conflicts and emotional isolation, enrichment
of interpersonal relationships, resolution of existential
death anxiety, positive changes in the life values and
purposes, broadening of the worldviews, and acceleration
of psychospiritual growth, through his approach to KPP.
Possible Mechanisms
of the Effectiveness of KPP
rupitsky previously reported that ketamine increases
delta and theta activity in the cortex, evidencing
limbic system activation as well as limbic-cortex
interaction (Krupitsky & Grinenko, 1997). It was further
documented that ketamine exerts its effect through
a functional and electrophysiological dissociation or
disconnect between the thalamo-neocortical and limbic
areas of the brain (Green & Krauss, 2004a, 2004b;
Mistry & Nahata, 2005).

Therefore, the Russian group including Kolp
hypothesized that ketamine’s underlying mechanism
of action on the brain is the blockade of the thalamocortical projections and the activation of the interactions
between frontal cortex and limbic structures, which
results in a specific hyperfrontal metabolic pattern in
the human brain, associated with ketamine-induced
psychedelic experience (intense visionary experience and
ego-dissolution). The thalamus’ primary function is to
relay sensory and motor signals to the cerebral cortex; the
frontal cortex is responsible for cognitive processing of
information (conscious mind); and the limbic system is
the brain’s center of emotions (unconscious mind). Thus,
ketamine blocks transmission of incoming signals from
all sensory modalities, including signals from the outer
world and one’s own body, and reinforces the interactions
between the so-called cognitive and emotional minds. In
other words, ketamine appears to disconnect the self from
so-called objective reality, ties self-aware and unaware
levels of mind in a closed loop, and removes a filter
between conscious mind and unconscious mind, resulting
in a profound waking dream that bears a remarkable
resemblance to OBE, NDE, or EDT experiences.
The ketamine-induced non-ordinary states of
consciousness seem to generate a different level of selfidentification. Kolp describes that as, during OBEs,
self-identity switches from “I am Body” to “I am
Mind,” while during NDEs the self-identity becomes
more similar to “I am Soul” and during the EDTs
more like Unio mystica or mystical union in which selfidentity further progresses to “I am God.” At no time,
of course, is it suggested in KPP that the Soul and/or
God experiences constitute any proof of the existence
of any specific theological concept. These psychedelic
experiences are subjective phenomena that cannot be
easily, if ever, scientifically objectified, and they certainly
do not prove the existence of any transcendental reality.
Nevertheless, for reasons that remain speculative, having
the uniquely profound and powerful mystical experience
can significantly contribute to broadening attitudes about
the self and the world, positive changes in life values and
purposes, resolution of existential death anxiety, and
rapid acceleration of spiritual transformation.
In 1962, Pahnke (1962, 1968, 1969; Pahnke et
al., 1970) conducted the double-blind “Marsh Chapel
Experiment” (a.k.a. the “Good Friday Experiment”)
investigating whether a psychedelic agent (psilocybin)
would cause a genuine mystical experience in religiously
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while still being alive. The soul’s suffering became
repetitive … re-living life of all animals that my
body consumed and my mind adored … again and
again … life after life … with no end at all. It
seemed like the soul has been tortured for thousands
if not millions of years before the mind re-emerged
and then re-entered the body. My whole essence
was screaming —no more carnivorous lifestyle
… no more causing suffering and death to God’s
innocent creatures.
B has continued to conscientiously participate in
aftercare since the completion of his treatment and
completely abandoned eating any animal products,
both meat and dairy. He continued meditating daily
and restarted exercising on a regular basis. B did not
give up eating biscuits and potatoes (no butter and no
sour cream), but he started limiting the consumption
of flour and starches to once a week, eating only two
biscuits and one potato on the weekends. Within 2
years, his weight stabilized at around 200 pounds
and has remained constant since. The number of
the medications has decreased from 8 to 1 and his
hypertension, type II diabetes, hyperlipidemia, and
sleep apnea have completely resolved.

K

predisposed subjects. Virtually all members of the
psilocybin group (graduate degree divinity students)
reported having profound religious experiences and the
faculty of the Harvard Divinity School concluded that
a psychedelic agent can indeed facilitate such mystical
experiences.
Twenty-five years later, Doblin (1991) traced
seven theological seminary students participating in
the Good Friday Experiment and reported that all of
the psilocybin subjects continued considering that their
original religious experience had a genuineness in terms
of mystical nature and characterized it as a high point of
their spiritual lives. One of these students was religious
scholar Huston Smith, an author of several textbooks
on comparative religion, who later on described his
original psychedelic experience as the most powerful
homecoming he had ever experienced (Smith, 2001).
In 2002, a group of investigators at Johns
Hopkins University conducted a more rigorously
controlled study similar to the Good Friday experiment
(Griffiths et al., 2006). The study’s participants were
hallucinogen-naïve adults who reported regular
participation in religious or spiritual activities. The study
compared psilocybin (30 mg) and methylphenidate (40
mg) using a double-blind between-group, crossover
design. Thirty volunteers received 30 mg of psilocybin
and 40 mg of methylphenidate in counterbalanced
order. Two or three sessions were conducted at 2-month
intervals. To obscure the study design, 6 additional
volunteers received methylphenidate in the first 2
sessions and un-blinded psilocybin in a third session. The
8-hour sessions were conducted individually. Volunteers
were encouraged to close their eyes and direct their
attention inward. The study’s investigators documented
that 67% of the participants who received psilocybin
experienced powerful NOSC that had similarities to
naturally occurring mystical experiences. Furthermore,
those drug-induced mystical experiences were rated
by volunteers as having great personal and spiritual
significance that resulted in sustained positive attitudes
and behavior that were corroborated by ratings from
friends and family.
Sixteen months later, the same group of
researchers at Johns Hopkins University completed a
follow-up to their original psilocybin study (Griffiths et
al., 2008). Two thirds of the study participants continued
rating the psychedelic-induced experience as among
the top most meaningful experiences in their lives.

Sixty-four percent of the participants reported that the
experience increased well-being and life satisfaction, and
58% met criteria for having had a “complete” mystical
experience. Seventeen percent indicated that it was the
most meaningful and significant experience, while none
of the participants rated the experience as leading to
decreased well-being or life satisfaction. The researchers
concluded that the mystical aspect of the experience was
crucial in achieving positive therapeutic outcomes, and
they recommended additional therapeutic trials with
hallucinogens.
Kolp thinks it is evident that an ego dissolution
during psychedelic-induced mystical (transcendental,
spiritual) peak experience is perceived by healthy
volunteers and mentally ill patients alike as transcending
their individual body restrictions and generates a
psychological sense of security which extends beyond the
impermanence of the finite corporeal body. Successively,
the individuals can better cope with the prospect of
the yet to come death and demonstrate a long-lasting
resolution of existential death anxiety (Cohen, 1965;
Griffiths et al., 2006, 2008; Grinspoon & Bakalar,
1979; Grob, 1998, 2002; Grof, 1978, 1980, 1986;
Grof & Halifax, 1976; Grof et al., 1973; Kast, 1966a,
1966b; Kast & Collins, 1964; Kolp et al., 2007, 2009;
Krupitsky & Grinenko, 1996; Krupitsky & Kolp, 2007;
Krupitsky et al., 1992; Pahnke, 1968; Pahnke et al.,
1970; Richards et al., 1972, 1977, 1979; Walsh & Grob,
2005; Watts, 1973; Yensen & Dryer, 1993/1994). The
following case study demonstrates the efficacy of egodissolving transcendental experience in the treatment of
a patient with chronic depression, recurrent headaches,
and combined opioid and barbiturate dependence:
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M was a 34 year-old Hispanic American female
who had been suffering from chronic depression
since her puberty. In addition, she developed the
onset of recurrent headaches within 2 years after the
commencement of her marriage at the age of 22.
She was raised as a non-denominational Christian
and changed her self-identity to “spiritual but not
religious” during her early 20s. She reported no
history of physical and/or sexual abuse during her
childhood, but acknowledged a long history of an
ongoing repeated stress due to a hapless marriage
(she described her husband as a “patriarchal male
chauvinist pig”), 2 children of ages 11 and 9 with
conduct disorder and ADHD (whom she referred to

as “little terrorists”), and a demanding full-time job
with an “awful boss.”
M began psychiatric treatment at the age
of 16 and and had already been prescribed
many antidepressants, including five SSRIs
(fluoxetine, paroxetine, sertraline, citalopram, and
escitalopram), three SNRIs (venlafaxine, duloxetine,
and desvenlafaxine), one NRI (bupropion) and one
NaSSA (mirtazapine). Although she responded well
to the treatment with her first SSRI and first SNRI
(both times the remission lasted for 9 and 6 months
respectively), the efficacy of antidepressant treatment
eventually became marginal. M also started
treatment with a neurologist at the age of 24 and
was treated with several anti-migraine medications,
including sumatriptan, metoprolol, topiramate,
gabapentin, rizatriptan, and pregabalin, all with
limited results.
At the time of her initial evaluation for KPP
treatment, M was taking a combination of bupropion
(300 mg in the morning), mirtazapine (45 mg at
bedtime), and Fioricet (codeine 30mg, butalbital
[a barbiturate] 50mg, acetaminophen 300mg, and
caffeine 40mg) which she took as 2 capsules 4 times
a day (240 mg of codeine and 400 mg of butalbital
daily). She continued complaining of chronically
depressed mood (she scored 28 points on the Beck
Depression Inventory) and recurrent headaches (3–4
times a week, lasting for several hours).
M elected to participate in a group residential
program and agreed to get detoxified from both
sedatives (codeine and butalbital) and both
antidepressants (bupropion and mirtazapine) since
her medications “did not work anyway.” In addition,
she dutifully followed strict preparatory guidelines
(a whole food plant-based diet, optimal hydration,
daily meditation and exercise, limitation of screen
time, and contemplation on the nature of the Self and
God). After successful preparation on an outpatient
basis, M was admitted to a residential program
where she became actively engaged in an intensive
group process. She received 150 mg of ketamine IM
and reported the following EDT experience:
My body became dissolved as an icicle in a hot
water and my mind began steadily expending
as an inflating balloon. First, I got aware of the
surrounding space around me and actually became
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the growing trees … and birds … and animals
… and other people … in the range of 300-400
yards around me. This expansion did not stop at
it and my mind continued progressively getting
larger and larger … until it embraced the entire
Earth and I became aware that I am a part of the
Great Mother Gaia. At that point my individual
mind disappeared and became transformed into
collective mind. The collective mind continued
rapidly expending to the entire Solar system
… then to the entire Milky Way galaxy … and
eventually to the entire Universe. The individual
awareness shifted to the awareness of the Universal
Mind and my personal Soul became a part of the
Universal Consciousness. God and I are One and
We are omniscient, omnipotent, omnificent and
omnipresent. The experience seemed lasting for the
eons … and all that time the awareness remained
“everything is exactly as it should be” … “We are
all One” … “everything is perfect” … “everything
is perfect” …
M continued in aftercare for 2.5 years until she and
her family relocated to another state. She reported
that her chronic depression had finally resolved
and her recurrent headaches were completely gone.
M also became actively engaged in ongoing family
psychotherapy and reported marked improvements
in her relationships with her husband and children,
as well as improvements in her other interpersonal
relationships. She continued exercising and
practicing meditation on a regular basis, stopped
consuming animal products, and began volunteering
in a local charity.
M’s case represents a typical KPP treatment outcome
among those patients who experienced an ego-dissolving
mind-expanding transcendental experience.
Antidepressant Effects of Ketamine
he low dose of ketamine used for analgesia and
anxiolysis as well as the medium dose of ketamine
used for conscious sedation can reliably produce brief
but robust antidepressant effects. Various investigators
started publishing reports documenting antidepressant
effects of ketamine in the early 1970s. These earlier
studies, performed from the 1970s through the 1990s,
utilized ketamine in medium doses and generally
attributed anxiolytic/antidepressant responses to an
overall psychological improvement following the
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induction of NOSC, a specific phenomenon called
“psychedelic afterglow.” This psychedelic afterglow state
consists of positive physical and psychological changes,
including increased psychological clarity, feelings
of being cleansed, increased confidence, feeling of
happiness and well-being, state of inner peace, feelings
of detachment, motivation to improve oneself, and
strong feelings of empathy for everyone. The afterglow
state was thought to be induced by the psychedelic
peak experience and reported to last from several days
to several weeks and longer (Adamson, 1985; Bolle,
1985, 1988, 1992; Grossbard, 1989; Fontana, 1974;
Khorramzadeh & Lofty, 1976; Krupitsky, 1993/1994;
Krupitsky & Grinenko, 1996, 1997, 1998; Krupitsky
et al., 1992; Moore & Altounian, 1978; Roquet, 1975;
Roquet & Favreau, 1981; Roquet et al., 1971; Yensen,
1973).
However, it was also long recognized that
ketamine was likely to acutely improve mood secondary
to its effects on, for example, the dopamine system,
which have some commonalities with amphetamine
and cocaine, and there was certainly long-standing
speculation as to a neurochemical basis for ketamine
improving mood for up to a week, with lack of a poststimulant crash being attributed to such possibilities as
the lingering presence of active ketamine metabolites
and/or gene induction (summarized in Jansen, 2001.)
In this context, it is of note that the original Maudsley
monograph describing amphetamine psychosis warned
against attributing mental state changes to anything
other than amphetamine while the metabolites could
still be detected in the urine, and that the metabolites
could sometimes be detected for at least a week (Connell,
1958), as is sometimes the case with ketamine.
The general trend changed with a formal study
done by Krystal’s group of investigators who reported
that research subjects with symptoms of depression
showed a dramatic antidepressant response to an
administration of low sub-psychedelic doses of ketamine
(Berman et al., 2000). It is interesting to note that the
original purpose of this study was not to research the
antidepressants effects of ketamine but to assess its
cognitive effects on subjects with mental illness. The
antidepressant effect of ketamine was apparently not
expected by this group (Brown, 2007). Some similar
studies have replicated these findings and confirmed that
low doses of ketamine can produce a rapid antidepressant
effect lasting from 1-2 days to 1-2 weeks (Kudoh et al.,

2002; Ostroff, Gonzalis, & Sanacora, 2005). These
results would probably not have been a surprise to most
non-medical and “recreational” users of the drug, who
have long reported elevation in mood for up to a week
(summarized in Jansen, 2001).
These earlier reports seemed to have only a
limited impact until a study was conducted at the
National Institute of Mental Health (Zarate et al.,
2006). This randomized controlled trial was specifically
conducted in subjects with TRD, including some
patients who had not responded to electroconvulsive
therapy. The study provided evidence that a single subanesthetic dose of ketamine may provide rapid but nonsustained relief of depressive symptoms.
Since publication of this study, further reports
have confirmed the efficacy of ketamine for the treatment
of major depressive disorder and the depressive phase
of bipolar disorder (aan het Rot et al., 2010; Bjerre &
Fontenay, 2010; DiazGranados et al., 2010; Ibrahim et
al., 2012; Liebrenz et al., 2007, 2009; Murrough et al.,
2011, 2012; Rasmussenet et al., 2013; Rot et al., 2008;
Zarate et al., 2012, 2013). Most recent studies have
used a low sub-psychedelic dose of ketamine (0.5 mg/
kg) administered via IV infusion over 40 to 60 minutes
(aan het Rot et al., 2010; Bjerre & Fontenay, 2010;
DiazGranados et al., 2010; Glue, Gulati, Le Nedelec,
& Duffull, 2011; Ibrahim et al., 2012; Liebrenz et al.,
2007, 2009; Murrough et al., 2011, 2012; Rasmussen
et al., 2013; Rot et al., 2008; Zarate et al., 2006, 2012,
2013), and one study utilized a low sub-psychedelic dose
of ketamine (1 mg/kg) via IM administration (Glue et
al., 2011). The number of ketamine administrations has
varied from one to six (aan het Rot, Zarate, Charney, &
Mathew, 2012).
There are also reports documenting the
effectiveness of ketamine pharmacotherapy in the
treatment of eating disorders (Mills, Park, Manara, &
Merriman, 1998) and obsessive-compulsive disorder
(Rodriguez et al., 2013). Murrough and colleagues
examined the efficacy of repeated ketamine infusions
on the length of post-treatment remission (Murrough
et al., 2012). The study’s subjects underwent a washout
of antidepressant medication followed by up to six IV
infusions of ketamine (0.5 mg/kg) administered three
times per week over a 12-day period. Seventy-one
percent of the patients developed a remission. However,
the median time to relapse after the last infusion of
ketamine was only 18 days. Some researchers have thus
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been adopting a maintenance strategy (Messer & Haller,
2010). There have been reports of oral (Irwin & Iglewicz,
2010; Paslakis, Gilles, Meyer-Lindenberg, & Deuschle,
2010) and sublingual (Lara, Bisol, & Munari, 2013)
ketamine as an effective maintenance antidepressant.
Since intranasal ketamine has been already used as an
effective maintenance sedative and analgesic (Bahetwar,
Randey, Saskena, & Chandra, 2011; Reid, Hatton, &
Middleton, 2011), this technique is also being developed
as both an initial and maintenance treatment of major
depression (Lapidus et al., 2014). These 3 modalities—
oral, sublingual, and intranasal—are emerging as the
preferred delivery methods of a ketamine maintenance
treatment.
It is unknown how many persons who take nonprescribed ketamine (i.e., non-medical and recreational
users) are actually taking the drug to self-medicate what
amount to depressive disorders. It is also unknown
how many clinical practitioners in the United States
have administered ketamine to patients with TRD,
but general correspondence suggests a marked increase.
An internet search identified an on-line organization
(Ketamine Advocacy Network; KAN) that has a list
of “ketamine doctors” in the United States who are
performing the ketamine administration procedure
(www.ketamineadvocacynetwork.org). At the time of
writing this paper, KAN was listing 17 physicians from 3
specialties, including 10 psychiatrists, 5 anesthesiologists,
and 2 neurologists. All physicians are providing both the
initial infusion of ketamine to rapidly relieve depression
and a maintenance therapy to lengthen a remission
after the symptoms of depression re-emerge. Sixteen
physicians administer IV infusions of ketamine, and 1
psychiatrist administers IM injections. One psychiatrist
is offering a post-infusion maintenance treatment with
transcranial magnetic stimulation, one anesthesiologist is
offering maintenance treatment with intranasal and oral
ketamine, and one neurologist is offering an intranasal
maintenance treatment.
It is understandable why the majority of known
ketamine providers have used IV infusions. All initial
research studies that reported a robust anti-depressant
effect of ketamine were using IV infusions of ketamine.
However, IV infusions are partly the preferred delivery
methods in a research setting because an IV line provides
access for collecting blood samples to measure various
biochemical markers before, during, and after the
procedures. Outside the research setting, IV infusions

may offer no particular advantage, and seem unlikely
to be more beneficial than IM injections. This fact was
emphasized by the initial group of formal researchers
(aan het Rot, Zarate, Charney, & Mathew, 2012), who
pointed out that previous research documented that
IV administration of conventional antidepressants did
not support increased efficacy over oral administration
(Moukaddam & Hirschfeld, 2004).
From the viewpoint of a physician practicing
in a clinical setting, the IV infusions have many
disadvantages. They are supposed to be performed
in a hospital setting and to require the presence of an
anesthesiologist, decrease the duration of therapeutic
NOSC from 45-60 minutes to 20-25 minutes (unless
performed as a continuous drip), and can increase the
procedure’s cost to the patients from approximately
$400 per IM administration to around $2,000
per IV infusion, or more. Meanwhile, ketamine
administration for treatment of mental illnesses remains
an “experimental” procedure and its cost is not yet being
covered by any medical insurance company, forcing
non-research patients in the United States to bear the
cost. In addition, IV infusions needlessly medicalize the
procedure and, consequently, may increase the chances
of a frightening experience. It has been suggested that
IV ketamine infusions should perhaps be reserved for
emergency room treatment only, where acutely suicidal
depressed patients frequently present themselves (Larkin
& Beautrais, 2011), although it is likely that even in
this context, IV will eventually be shown to have no
powerful advantage over IM when all the costs and
benefits are weighed, as has gradually been demonstrated
in psychiatric ICU hospital practice for benzodiazepines
and antipsychotics, in which context giving the
medicines as an IV injection is fading away in Englishspeaking countries (e.g., Taylor, Paton, & Kapur, 2012).
Other practitioners have already started
utilizing IM injections of ketamine as the preferred
treatment. A leading article in the January 2013 issue of
Psychiatric Times (Kaplan, 2013) described a ketamine
treatment program at the University of California San
Diego (UCSD) Medical Center, directed by David
Feifel, an associate professor in the Department of
Psychiatry. Feifel recommended starting with the initial
infusion to assess the length of a remission. Those
patients who demonstrate at least one week of a stable
remission are then referred for a maintenance treatment
with repeated administrations of a low intramuscular
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dose of ketamine (0.5 mg/kg) and no more frequently
than once every 2 weeks. Feifel has begun utilizing an
IM administration because of its practicality and cost
effectiveness. He shared that when the UCSD program
first started, anesthesiologists were required to give the
intravenous ketamine infusions in an acute care setting,
with the costs of IV procedures around $2,000 per
infusion; in contrast, IM administrations are now given
by nurses, with an attending physician available during
the procedure, and the cost went down significantly
(Kaplan, 2013).
Ketamine psycho-pharmacotherapy is rapidly
gaining momentum. The FDA awarded the breakthrough
therapy designation for the development of intranasal
ketamine for treating depression (a definition of
breakthrough therapy is a drug that treats a serious or
life threatening disease and preliminary clinical evidence
indicates that the drug may demonstrate substantial
improvement over existing therapies on one or more
clinically significant endpoints, such as substantial
treatment effects observed early in clinical development).
If a drug is designated as breakthrough therapy, the FDA
will expedite the development and review of such a drug.
All requests for breakthrough therapy designation will
be reviewed within 60 days of receipt, and the FDA will
either grant or deny the request. This is the first time this
special designation, usually reserved for drugs targeting
a lethal epidemic or a deadly form of cancer, has been
awarded for the development of a medication for a
mental disorder.
A key remaining question is the duration of
ketamine’s effect, which significantly varies not only
from person to person, but also from treatment to
treatment for the same person. At times, the effect only
lasts a day or two and at other times, the effect lasts 1-2
weeks, or even a month.
The Biological vs. Psychological
and Transpersonal Effects of Ketamine
s noted, some of the earlier ketamine studies
attributed the anxiolytic and antidepressant posttreatment effects to “psychedelic afterglow” following
the induction of NOSC. Contrary to the earlier reports,
most of the recent studies ignore the psychological effects
of ketamine-induced altered states of consciousness and
appear to largely dismiss these psychological phenomena,
particularly those of a transpersonal quality which
are presented mostly as an undesirable side-effect. For
example, Arun Ravindran, psychiatry professor at the

University of Toronto and chief of mood and anxiety
disorders at Toronto’s Centre for Addiction and Mental
Health, will be leading a study specifically exploring oral
and intranasal routes of ketamine administration. In a
recent interview with The New York Times (October 10,
2014), Professor Rivandran was referring to ketamineinduced psychological phenomenon as an unwanted
side-effect that he called the “relaxed dissociated state.”
Virtually all scientific investigators who have
recently published in this area present similar opinions
in their published writings, and largely attribute the
antidepressant effects of ketamine to its pharmacological
properties to alter the glutamate system, which in turn
modulates other systems such as dopamine (aan het Rot
et al., 2010; Bjerre & Fontenay, 2010; DiazGranados
et al., 2010; Glue et al., 2011; Ibrahim et al., 2012;
Liebrenz et al., 2007, 2009; Murroughet et al., 2011,
2012; Rasmussen et al., 2013; Rot et al., 2008; Zarate et
al., 2006, 2012). This current biological theory proposes
that, in addition to biochemical sub-types of depression
caused by an “imbalance” of biogenic amines (serotonin,
norepinephrine, and dopamine), there is also a separate
sub-type of depression that biochemically mediates the
same syndromic diagnosis of major depressive disorder due
to an “imbalance” of glutamate (aan het Rot et al., 2010;
Bjerre & Fontenay, 2010; Hashimoto, 2009; Ibrahim et
al., 2012; Liebrenz et al., 2007; Machado-Vieira, Manji,
& Zarate, 2009; Murrough et al., 2011; Rasmussen et al.,
2013; Rot et al., 2008; Scolnick, Popik, & Trullas, 2009;
Zarate et al., 2006, 2012).
There are complications with this theory. An
existing NMDA receptor antagonist, memantine, was
first developed in 1968 and has long been used as a
neuro-protective agent and prescribed by some doctors
for moderate-to-severe dementia. Like many other
NMDA antagonists, memantine is a dissociative agent
at above therapeutic doses (Morris & Wallach, 2014).
It can even substitute for phencyclidine in rodent
and primate drug discrimination studies (Parsons
& Danysz, 1999). Although memantine has been
associated in some studies with a modest decrease in
the clinical deterioration of patients with moderate-tosevere dementia (Rossi, 2006), it has been reported as
having only an insignificant positive effect on mood
in the treated patients (Areosa, Sherriff, & McShane,
2005). There is still relatively little evidence of even a
minimal effect on mild Alzheimer’s disease (Schneider,
Dagerman, Higgins, & McShane, 2011). Zarate and his
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team have also reported that memantine does not relieve
depression (Brown, 2007). The claim that memantine
would be effective in Alzheimer’s disease was rather
surprising as it is well established that NMDA receptor
blockade impairs memory rather than improving it (e.g.,
Collingridge, 1987). Ketamine users tend to report
problems with their short-term memories rather than any
improvement (Jansen, 2001; Morgan & Curran, 2012).
Another available glutamate-modulating agent,
riluzole (Rilutetek), a drug that inhibits glutamate
release, does somewhat improve depression but no better
than conventional antidepressants and with the same
time delay (Sanacora et al., 2007; Zarate et al., 2004,
2005). Riluzole was also researched in patients treated
with ketamine in an attempt to sustain antidepressant
effects. However, the studies failed to demonstrate any
benefit over placebo in maintaining response to an IV
ketamine infusion (aan het Rot et al., 2012; Brown,
2007; Ibrahim et al., 2012; Mathew et al., 2010).
A recent study using sophisticated proton
magnetic resonance spectroscopy has specifically
investigated ketamine’s effects on glutamate brain levels
in depressed patients but found no association between
the antidepressant effects of ketamine and any significant
changes in brain glutamate levels in both immediate
(3 hours) and delayed (2 days) response to a ketamine
administration (Valentine et al., 2011).
Undoubtedly, ketamine has many direct and/
or indirect pharmacological effects on the human
brain that may immediately improve the subject’s
mood. These effects are multifactorial. In addition to
affecting the glutamate system (similarly to alcohol),
ketamine affects the dopamine system (similarly to
NRIs and amphetamines), GABA system (similarly to
benzodiazepines), serotonin system (similarly to SSRIs),
mu opioid system (similarly to opiates), cannabinoid
system (similarly to THC), and nitric system (similarly
to nitrous oxide or “laughing gas”). All of the above
compounds have been shown to rapidly generate antianxiety and anti-depressant effects (especially when
administered intravenously). The duration of their
effects, however, has generally not much exceeded the
pharmacological life of a particular compound and, it
must be noted, its psychoactive metabolites which can be
much longer.
Approximately one third of the ketamine
subjects did not maintain a remission of depressive
symptoms for longer than 24 hours post-infusion. Two

thirds of the subjects did maintain a remission lasting
from 2-5 days to 1-2 weeks. Why would remission last
longer than one day? One possibility is some persistence
of the NMDA-receptor active metabolites, with
variations between people in the rate of metabolism due
to genetic and life-style differences (Jansen, 2001). There
are other psychiatric treatments where the persistence of
metabolites, sometimes for many weeks, is accepted as
central to the mechanism of action. The antipsychotic
drug haloperidol is a good example, with the active
metabolite lasting in the blood for many weeks. Thus
ceasing to take haloperidol rarely results in an immediate
relapse of psychosis.
However, it is also possible that the so-called
“relaxed dissociated state” is not an unwanted sideeffect, but is actually a cause of protracted remissions
for psychological reasons. This may well prove to be
the correct explanation. A recent study done by the
Zarate group of investigators (Luckenbaugh et al., 2014)
presented data from 108 treatment-resistant inpatients
who met criteria for major depression or type I and II
bipolar disorder and were given a sub-anesthetic ketamine
infusion. The group examined whether dissociation
experiences, measured by the Clinician-Administered
Dissociative States Scale (CADSS), correlated with
improvements in the Hamilton Depression Rating Scale
(HDRS). The correlations’ analysis indicated that there
was a significant association between increased CADSS
scores and improvement in HDRS scores, while none of
the other analyzed parameters significantly correlated
to HDRS change. The study concluded that those
patients with more dissociation are also those in whom
ketamine has a greater antidepressant efficacy, while the
patients who did not show the dissociation did not have
antidepressant efficacy in the post-infusion period.
This paper resonates with the earlier ketamine
studies attributing a post-treatment remission of anxiety
and depression to the quality of NOSC experience. It may
be that one third of the experimental ketamine subjects
had an alcohol-like euphoric affect and their remission
thus lasted for no longer than 24 hours post-infusion.
Another one third of the subjects had an MDMA-like
empathogenic experience, and their remission lasted for
2-5 days post-infusion. The last one third of the patients
had an OBE, and their remission lasted for 1-2 weeks
and even longer. These odds are expected due to the
fact that the standard 50 mg dose of ketamine used in
the research subjects is located on the critical dosage
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threshold between empathogenic and hallucinogenic
responses, giving many subjects a 50% chance to have
either an empathogenic or a hallucinogenic experience.
It seems that reducing the experiences of
ketamine to just being due to biological causes may
be doing injustice to their psychological, and even
transpersonal, effects. The following clinical case supports
the theory that psychological factors are important:
W was a 59 year-old Caucasian female, with a
past history of sexual abuse (between ages 11 and
17) and a life-long history of avoidant personality
disorder (now re-classified as anxious personality
disorder). She also developed scoliosis (a sideways
curvature of the spine) during the growth spurt just
before puberty and suffered from chronic pain since
her mid-teens. In addition, she developed regular
panic attacks, occurring 1-3 times a week, lasting
from 10-20 minutes to several hours, since her late
teens. W was raised as a Methodist, but converted
to Hinduism at age 18, when she joined an ashram
(a version of a contemporary monastery) in order to
escape from her abuser (step-brother). W embraced
a Yogini lifestyle and started practicing daily
transcendental meditation, two times a day, 1 hour
each sitting.
At the age of 27, during an exceptionally
long 10-day silent retreat, she spontaneously
developed the Samadhi experience (ego-dissolving
transcendental state of consciousness of mystical
union with God) that lasted for several hours. W
reported that after experiencing this state of “ecstatic
bliss,” her anxious personality, chronic pain, and
recurrent panic attacks were “gone in a blink of an
eye.” Her remission lasted for 9 years until she was
raped at the age of 36, which triggered a relapse of
panic disorder, chronic pain disorder, and avoidant
behavior. The rape also caused the onset of chronic
depression.
W continued meditating devotedly every single
day and attended numerous silent retreats. However,
she never had a mystical experience again. She had to
start taking pharmaceuticals to control her chronic
anxiety, depression, and pain, and she was treated
with paroxetine, diazepam, and hydrocodone. The
medications controlled her problems, but only
partially. In addition, W slowly developed tolerance,
which required a periodic upward adjustment of
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medication dose. By the time she requested ketamine
treatment, she had to take daily 60 mg of paroxetine,
80 mg of diazepam, and 120 mg of hydrocodone.
Despite high doses of three pharmaceuticals, she
continued having chronic depression (her Back
Depression Inventory [BDI] score was 29), chronic
anxiety (her Beck Anxiety Inventory [BAI] was 36)
and chronic pain (rated 7 on 0-10 scale).
W considered undertaking KPP, after
discovering a description of the EDT experience
on Kolp’s website, in which she recognized her
spontaneous Samadhi experience. She had no
difficulties to prepare herself for the experience, as
she already practiced a vegan lifestyle, meditated
and exercised daily, contemplated on the nature of
the Self and God much of her waking time, and
used screen time only occasionally. For the last 10
days of the preparation, she started practicing a
juice fast in order to increase a chance of the EDT
experience.
The day before the administration of ketamine,
W consulted her guru (a spiritual guide), who
actively discouraged her from having the druginduced EDT experience. She was apparently told
that the “Creator cannot be experienced through a
narcotic, you should instead double your meditation
time.” She accepted the guru’s instruction and
requested to have only 50 mg of ketamine, since
W believed that this dose represented a medicallyrecommended dose that should be used as a
therapeutic agent for the treatment of chronic
“treatment-resistant” depression. Her therapist
supported her wish, reminded W that she had a
good chance of having the EDT experience due to
her outstanding preparation, and instructed W “to
close her eyes, start meditating, and surrender to
whatever is to come.” W followed this instruction,
positioned herself in a Savasana (“corpse”) pose, and
then comfortably remained in the pose for the next
2 hours. Upon her return from the journey she
shared this experience:
As soon as I started breathing slowly and reciting
my mantra my body started quickly relaxing and
within 3 or 4 minutes the body became deeply
relaxed and very comfortable. For the first time
in the past 23 years the pain has disappeared. My
mind was feeling very peaceful and calm … yet
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As this case demonstrates, a spontaneous EDT experience
can prolong the length of remission from depressive
symptoms significantly longer than the best druginduced empathogenic experience. Although all NOSCs
may contribute to accelerated healing, it seems that the
EDT experience may have the most healing potential.
The majority of Kolp’s patients with chronic
treatment-resistant depression (approximately 90%),
who requested ketamine pharmacotherapy with a subpsychedelic dose (50 mg IM), never had a trial with
any MAOI antidepressants. Subsequently, Kolp began
offering a trial with a MAOI antidepressant to all MAOInaïve patients and recommended starting the trial on the
day following the IM ketamine administration. Nearly
80% of the patients responded well, maintained a steady
remission, and did not require a maintenance treatment
with repeated IM administrations of ketamine.

Ketamine Addiction
he concerns of W’s guru about drug-seeking
behavior in some ketamine users do have merit, as
ketamine can generate strong effects on mood (feelings),
cognition (thinking), and perception (imagery) that make
some people want to use it repeatedly. However, initially
both the FDA and the DEA accepted the Parke-Davis
testimonials and apparently agreed that ketamine has no
addictive properties. It was subsequently discovered that
ketamine is a substance with very significant dependence
potential for multiple reasons (Jansen, 2001). In fact, the
68th edition of the Physicians’ Desk Reference specifically
warns physicians that prolonged use of ketamine may
lead to tolerance and drug dependence (PDR Network,
2013). Kolp found that more than two thirds of his
ketamine patients wanted to have another empathogenic
experience the following day and nearly one third of
the patients wished to promptly repeat a psychedelic
experience.
Ketamine has been available to hospital staff
since late 1960s, and persons working in this context
were amongst the first ones to personally test the drug’s
empathogenic and psychedelic effects. The street use of
ketamine hydrochloride solutions was first noted in San
Francisco and Los Angeles circa 1971, while other forms
of ketamine (powder and tablets) were first noticed on
the street in 1974 (Ashley, 1978). Ketamine went under a
variety of street names, including Special K and Vitamin
K (Siegel, 1978).
One of the first reports describing the
testimonials of non-prescription ketamine users came
from Rumpf and his group of investigators (1969), whose
subjects described ketamine hallucinations as “utopic,”
“fantastic,” or “mysterious.” Only one out of their 18
subjects considered the dream experiences normal
and ordinary. The experience was termed pleasant by
six subjects, unpleasant by eight, and neutral by four.
Unexpectedly, Rumpf and colleagues reported that
fully one third of the group (six subjects) had “true
hallucinations” with the concomitant delusions that
their dreams were not dreams, but, in point of fact, real
events (Rumpf et al., 1969).
The first comprehensive study examining the
patterns of ketamine addiction was done by Siegel
(1978), who examined 23 subjects with recreational
ketamine use. His sample included 13 injection users
of ketamine and 10 intranasal ketamine users. Use
of ketamine was primarily experimental or social in
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the mind remained fully awake and alert. Again,
for the first time in the past 23 years, the sad mood
and persistent anxiety have gone away. At that
point I stopped meditating and started enjoying the
profound feelings of empathy, compassion and love
for myself. The whole experience was full of joy and
peace … I only regret that I stopped meditating
and did not transcend to the Soul Consciousness
and then to the God Consciousness…
W maintained a symptom-free remission for
3.5 weeks and then developed a relapse of anxiety,
followed by pain, and then depression. It was
suggested that she undertake a second ketamine
treatment. However, her spiritual guide persuaded
her against it, pointing out that it may represent
a drug-seeking behavior. The guru’s advice was
“keep meditating.” At that point, W was started
on phenelzine, 15 mg daily, with only a minimum
response. After 4 weeks of treatment, the dose of
phenelzine was increased to 30 mg daily, with a good
response. W maintained a partial remission and her
BDI score decreased to 17, the BAI score declined
to 19, and her chronic pain level reduced to 3-4 on
a scale of 10. She required two more adjustments of
the phenelzine dose, to 45 mg 10 months later, and
to 60 mg 17 months later. During her 2-year followup, W continued maintaining a steady remission:
her BDI score further decreased to 14, the BAI score
remained 19, and the chronic pain level became
stable at 3.

T

nature, and the drug was viewed by users to be a potent
yet safe hallucinogen with a short duration of action
and few if any adverse effects. Ketamine users tended
to titrate their use in order to achieve the desired effects
of stimulation, dissociation, visual hallucinations,
and transcendental experiences (Siegel, 1978). When
asked to rank all drugs in terms of general recreational
preference, Siegel reported that intranasal users ranked
cocaine first, while injection users ranked LSD first.
The users consistently described ketamine in the
following ways:

Ketamine users repeatedly sought and experienced
the following desirable effects: floating sensations and
dissociation (87%), stimulation (83%), hallucinations
(78%), increased cognitive or mental associations
(74%), euphoria (26%), and transcendental or religious
experiences (17%). Despite the widespread beliefs among
users about the lack of adverse reactions, a number of
untoward effects were also reported, including ataxia
(100%), slurring of speech (70%), dizziness (61%), mental
confusion (35%), hyperexcitability (26%), unpleasant
imagery (26%), blurring of vision (17%), negative
hallucinations, or the inability to see things that were
really there (17%), decreased sociability (17%), anxiety
(13%), nausea (13%), insomnia (13%), and decreased
sexual motivation (9%).
Siegel (1978) documented the specific long
term effects, both positive and negative, resulting
from ketamine use. Some ketamine users described a
lasting elevation of mood (43%), deeper insights into
self and others (35%) and positive changes in attitudes
and personality (17%). Other ketamine users reported
undesired long term effects including flashbacks (57%),
attentional dysfunction (22%), and decreased sociability
(9%). Overall, long-term effects appeared equally divided
between positive and negative experiences.

Ketamine was further popularized during the
1970s by John Lilly, and to a lesser extent by astrologer
Marcia Moore, who wrote books on the subject of selfuse of ketamine. Lilly published a book entitled The
Scientist (1978) and Moore (together with her husband,
Dr. Alltounian) published a book called Journeys into
the Bright World (1978). Both books documented the
unusual phenomenology of ketamine intoxication
and prompted others to experiment with ketamine.
Subsequently, many ketamine users in the “first wave”
preferred ketamine for its psychedelic properties and
administered it via IM self-injections.
The ketamine scene began changing during the
late 1980s to early 1990s when lower doses of ketamine
in pill and powder form, for intransal use, became more
prevalent due to its empathogenic and stimulant effects
at lower doses (Tori, 1996; NDIC Bulletin, 2004).
Ketamine began appearing on the club, underground
party, and rave scenes, being used together with or
instead of ecstasy (MDMA), cocaine, and amphtamines.
By the mid-1990s, ketamine had entered mainstream
dance culture, and it remains a popular dance drug
today (e.g., Joe-Laidler & Hunt, 2008).
Eventually, the U.S. Drug Enforcement
Agency (DEA) became alarmed by this development
and changed ketamine’s schedule in August of 1999,
making it a controlled substance and moving the drug
to Schedule III of the Controlled Substances Act of
1970. Other countries have also done so, most recently
India which had been a major source for the European
market. India is now being replaced by China as the
source. In 2000 the Hong Kong government placed
ketamine in Schedule 1, a drastic measure in response
to the recent rise in ketamine prevalence in East Asia.
As previously noted, the Russian government
moved ketamine from Schedule III into Schedule II in
2002 after ketamine became popular with Muscovite
teenagers. In 2005, Canada re-classified ketamine as a
Schedule I narcotic. The United Kingdom has moved
ketamine from Class C to Class B in June of 2014, and
controls were also tightened in New Zealand. These more
recent changes were partly driven by the reports of binge
non-medical ketamine use being linked with damage to
the urinary system in some users. In addition, ketamine
is in Category 3 under Mexico’s General Health Law.
However, generic ketamine is still easily obtained in a
“veteranaria farmacia” as “ketamina” for $15 to $20 a
gram. According to a DEA report from 2004, over 80%
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Ketamine was perceived by users to be a safe,
non-toxic, potent hallucinogen with a short
duration of action and few adverse reactions.
Ketamine was perceived by most users as the
only hallucinogen that did not produce anxiety
or fear reactions.
Ketamine was considered to have unique
euphoric-hallucinogenic properties that enabled
a user to experience, with varying dosages,
effects similar to either cocaine, amyl nitrite,
phencyclidine, or LSD.

of ketamine seized in the United States at that time, ten
years ago, was of Mexican origin (NDIC Bulletin, 2004).
Unlike phencyclidine, ketamine production
is a complex and time-consuming process, making
clandestine manufacturing of ketamine impractical.
Meanwhile, ketamine is produced commercially in a
number of countries, including (for example) the United
States, Mexico, Columbia, China, India, Germany,
and Belgium, where it may be diverted from legitimate
sources. There have also been reports of industrial-scale
illicit ketamine manufacture in China (UN Office on
Drugs and Crime, 2010).
Ketamine’s use as a recreational drug has been
rising over the last 30 years (Copeland & Dillon, 2005;
Dillon & Degenhardt, 2001; Jansen, 2000; Moore &
Measham, 2008). Travis (2005) reported that ketamine
was one of the six most common drugs for sale in
UK cities. Stirling and colleagues (2008) published
an update on recreational drug use in the United
Kingdom and reported that 4% of the young adults
in the study had tried ketamine at least once. Dillon,
Copeland, and Jansen (2003) reported that about 1 in 3
Australian respondents in a study of a drug user culture
acknowledged the use of ketamine in the previous 12
months. The 2006 National Survey on Drug Use and
Health (NSDUH) reported that in the United States an
estimated 2,300,000 persons aged 12 and older had used
ketamine in their lifetime, and 203,000 were past year
users (NSDUH Report, 2006).
There is a substantial popular literature describing
ketamine dependence (e.g., Lilly, 1978; Sputz, 1989; Turner,
1994). Ketamine recurrent binges can be sustained for
many days and even several weeks. The medical literature
has documented the same and the number of case studies
is mounting (Ahmed & Petchkovsky, 1980; Hurt &
Ritchie, 1994; Jansen, 1990a, 1990b, 2000, 2001; Kamaya
& Krishna, 1987; Moore & Bostwick, 1999; Morgan &
Curran, 2012; Soyka, Kripinsky, & Volki, 1993). The
evidence from animal studies indicates that ketamine can
form a dependence syndrome (Beardsley & Balster, 1987).
The multiple problems related to dependence on ketamine,
including education, relationships, employment, finances,
and involvement in crime, have also been documented
(Lim, 2003).
In his private practice, Kolp has been handling
ketamine as a Schedule II substance and has been
repeatedly warning all patients that ketamine should
never be used except under the direct supervision of a
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licensed physician. Instead of a ketamine maintenance
treatment, Kolp encourages all MAOI-naïve patients
to have a trial with MAOIs first, prior to commencing
recurrent administrations of ketamine. To those
patients who do not accept a trial with MAOI, or who
failed it, Kolp offers a maintenance treatment with IM
ketamine. However, he prefers limiting the frequency of
ketamine IM administration to once every 4-6 weeks
and never more frequently than once every 2 weeks.
Kolp does not utilize oral, sublingual, or intranasal
ketamine maintenance treatment for his patients in
order to minimize the potential for ketamine abuse
and dependence. The procedural parenteral approach
(administering IM and IV ketamine in the office) would
reduce the abuse and dependence potential by strictly
controlling access to ketamine. In contrast, dispensing
the drug to the patients (in-home oral, sublingual, and
intranasal self-administration) would likely increase the
abuse and dependence potential by increasing access
to ketamine, and normalizing the use rather than this
being a “special event.”
Potential Side-Effects
of Ketamine Long-Term Treatment
he previously presented data on ketamine’s safety
profile has been established for episodic and/or
time-limited use of ketamine. Meanwhile, the sideeffects of acute and intermittent uses of a chemical
substance and side-effects of the chronic use of the same
compound may have two entirely different profiles. Once
ketamine (and other similar glutamergic compounds)
are sanctioned for use as oral anti-depressants, tens of
millions of patients may start using this class of chemical
compunds for an extended period of time. There may be
value in comparing both the acute and chronic use of
ketamine with another compound described as having
some similar glutamergic properties.
Ethanol, similar to ketamine, has the capacity
to block glutamate effects at the NMDA receptor, which
contributes to ethanol’s acute behavioral effects and
to the natural history and neuropathology of alcoholism
(Tsai, Gastfriend, & Coyle, 1995). Ethanol decreases
the NMDA-stimulated ion currents across the range
of ethanol concentrations (from 5 to 100 mmol/L)
that has been associated with human ethanol intoxication (Lovinger, White, & Weight, 1989; Nakanishi,
1992; Simson et al., 1991). Meanwhile, chronic longterm ethanol consumption increases the levels of
NMDA receptors, up-regulates NMDA receptor-
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related binding, and produces cross-tolerance with
other noncompetitive NMDA antagonists (Danysz,
Jankowska, Glazewski, & Kostowski, 1992; Fidecka
& Langwinski, 1989; Grant, Valverius, Hudspith, &
Tabakoff, 1990; Iorio, Reinlib, Tabakoff, & Hoffman,
1992; Trevisan et al., 1994).
This increased NMDA receptor function
produced by chronic long-term ethanol consumption
contributes to alcohol withdrawal seizures (Grant et al.,
1990) and ethanol neurotoxic effects (Chandler et al., 1993).
The NMDA antagonists ketamine and phencyclidine
substitute for ethanol in preclinical drug discrimination
paradigms (Grant & Colombo, 1993; Grant, Knisely,
Tabakoff, Barrett, & Balster, 1991). This biochemical data
may allow extrapolation of the effects of chronic long-term
ethanol consumption to some possibly analogous effects of
long-term chronic administration of ketamine and other
related NMDA antagonist compounds.
Ethanol has well-known anxiolytic and
antidepressant effects with a robust onset of action and
good anti-shock (neuro-protective) qualities when used
sporadically. It usually only has a few serious side-effects
when used episodically. The side-effects of acute ethanol use,
however, are very different than the side-effects of chronic
use. Ethanol, a known NMDA antagonist, is notorious
for its ability to trigger apoptotic neurodegeneration when
used chronically (Hoffman, Rabe, Moses, & Tabakoff,
1989) and is a leading cause of dementia (Moriyama,
Mimura, Kato, & Kashima, 2006).
A laboratory study conducted on primates
suggested that chronic use of ketamine may induce
neuronal cell death that is both apoptotic and necrotic in
nature (Slikker et al., 2007). Other experimental data have
confirmed this earlier study and documented that chronic
ketamine exposure might produce irreversible deficits
in brain functions due to neurotoxic effects, involving
the activation of apoptotic pathways in the prefrontal
cortex (Sun et al., 2014). A recent epidemiological study
conducted on frequent and infrequent ketamine users
reported that frequent ketamine use is associated with
impairments in working memory, episodic memory,
and aspects of executive function as well as reduced
psychological wellbeing (Morgan, Muetzelfeldt, &
Curran, 2009). The preliminary data are suggestive that
once ketamine and other similar glutamergic compounds
become available on the market as oral anti-depressants,
chronic long-term use might cause neurodegenerative
changes in the brain of some patients.

The Future of Ketamine Psychotherapy
from a Pharmacological Perspective
lthough there is currently a lack of scientific data
supporting a glutamate “imbalance” as a primary
pathophysiological cause of major depression, there
is a very short duration of post-ketamine remission of
depression, and there are questions regarding the longterm adverse effects of chronic use of ketamine, there is
excitement in the psychiatric research community about
the discovery of a new class of antidepressants with a
mechanism that may be beyond the effects of biogenic
amine neurotransmission.
Professor Preskorn (2012) of Kansas University
School of Medicine, who has been the principal
investigator on over 250 clinical trials including drug
development studies of all antidepressants marketed in
the United States in the last 25 years (www.preskorn.
com), pointed out that all of the existing antidepressants
are variations on the pharmacology of amphetamine,
iproniazid (MAOI), and imipramine (TCA) and
predicted that ketamine and related drugs could
revolutionize psychiatry. Yale professors Ronald Duman
and George Aghajanian, in a recent 2012 review of the
ketamine research in Science, stated that the emerging
ketamine treatment is the most important psychiatric
discovery in recent times.
Nevertheless, it is very unlikely that ketamine
will be developed for a mass market. It is an old drug
that has long been off patent, so it is not currently
profitable for drug manufacturers. The issue of some
risk to the kidneys and bladder among some nonmedical users is not going away and affects perceptions,
although the quantities involved and the circumstances
for these people may differ markedly from its use for
antidepressant, psychedelic, and other treatment
regimens, and the risk in the latter situations will likely
be minimal. Furthermore, its reputation as an abused
hallucinogen may now be too firmly embedded in the
public awareness for any kind of marketing campaign of
the sort commonly associated with antidepressants with
billions of dollars at stake.
In addition, the accepted model for all available
antidepressants is oral administration. Even ECT
treatment involves both an anaesthetic (sometimes
ketamine is used for this, and poses an important
confounding variable in some ECT studies) along
with the production of seizures with electricity. The
intravenous and intramuscular routes of antidepressant
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administration will severely limit the market size. The
profit to be made from ketamine by the pharmaceutical
industry from its use as an antidepressant thus appears
to be somewhat limited. An aim of the present
ketamine campaign will be to encourage research and
development of similar NMDA receptor antagonist
compounds that may be more profitable. Ketamine
on its own has eight presently known metabolites,
including esketamine, arketamine, bromoketamine,
deschloroketamine, ethketamine, fluoroketamine,
methoxetamine and methoxyketamine. Meanwhile, the
entire arylcyclohexylamines group of presently known
chemical compounds has nearly 60 various compounds.
Reportedly, at least 30 other unscheduled analogs have
been produced by clandestine sources.
As of July 2014, Johnson & Johnson is
developing a nasal spray formulation of esketamine
for the management of treatment-resistant depression
(Wijesinghe, 2014). Esketamine (a.k.a. (S)-ketamine or
S(+)-ketamine) is the S(+) enantiomer of ketamine and
twice as potent as racemic ketamine. A Phase 1 clinical
trial of intranasal esketamine is sponsored by a Johnson
& Johnson subsidiary, Janssen Pharmaceutical Research
& Development, LLC. This company is conducting
a clinical trial with 58 participants in Belgium; the
purpose of this study is to assess the efficacy and dose
response of intranasal esketamine (14 mg, 28 mg, 56 mg,
and 84 mg) compared with placebo (clinicaltrials.gov/
show/NCT01998958).
Another privately held biopharmaceutical
company, Naurex Inc., has recently announced that
it has successfully completed a Phase 2b clinical study
of GLYX-13, the company’s lead compound (www.
naurex.com). The FDA has already granted Fast Track
Designation to the research and development of this
compound. The company also reported that it initiated a
Phase 2a study of another orally active agent, NRX-1074,
after collecting positive results from a recently completed
Phase 1 study of the NRX-1074 drug. Both compounds
are NMDA receptor antagonists. However, their
specifics are unknown. Krystal, who may be one of the
most powerful figures today in biological psychiatry, has
endorsed research and development of both compounds,
and Preskorn is a study investigator (www.naurex.com).
Cerecor Inc., a Maryland-based biopharmaceutical company, is also in the process of developing
a new antidepressant drug, CERC-301 (formerly
known as MK-0657), as a therapy for TRD. The drug
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is a selective NMDA receptor antagonist and an orallyactive compound (Ibrahim et al., 2012). The company
has initiated phase II clinical trials in November of 2013
and this study has received Fast Track Designation from
the FDA for TRD (www.cerecor.com).
AstraZeneca, PLC (AZN) is studying another
NMDA receptor antagonist, lanicemine (Wijesinghe,
2014). Lanicemine was originally developed as a
neuroprotective agent and then was redeveloped as
an antidepressant following the report of Zarate and
colleagues (2012), who documented that lanicemine
has potent antidepressant effects similar to ketamine.
However, the drug is claimed to have little or no
psychotomimetic side effects (Zarate et al., 2012).
Although ketamine itself will probably not
become the next generation of anti-depressants,
it seems that numerous other members of the
arylcyclohexylamines class will be presented for this
purpose, and probably also presented as the next
generation of anti-anxiety drugs, mood-stabilizers,
and procognitive agents. Their impact on the urinary
system will need to be assessed where long-term
daily use is planned. It remains to be seen whether
the next generation of glutamate-antagonist based
pharmaceuticals will result in a growth of addiction to
those which are psychoactive arylcyclohexylamines.
In addition to this flurry of activity to develop
psycho-pharmacological applications of ketamine,
especially in ways that can yield profits, there remains
its psychological and transpersonal healing potential.
Our position is that these offer its greatest likelihood
of benefit, rather than through ketamine’s biological
application.
Conclusion
etamine is a potent substance that offers much
promise for alleviating suffering due to mental
health issues, but it also poses considerable danger when it
is misused. As a psychiatric medication, ketamine offers
a wide range of applications, from mild doses alleviating
depression (at least in the short-term) to psychedelic
dosages offering the possibility of transpersonal healing.
The fact that ketamine is the only psychedelic that
can legally be prescribed in the United States makes it
unique at this time, and we encourage its responsible use
within medical contexts for providing access to deep and
profound healing experiences that may be difficult, if not
impossible, for many to achieve without the aid of such
a substance.
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We hope that ketamine will remain legally
available for clinical applications and scientific research,
including for the field of psychedelic psychotherapy.
The current interest in ketamine may eventually
bring psychedelic psychotherapy somewhat closer to
the mainstream of psychiatry and psychology. Those
dismissive of its spiritual component, who are inclined
to consider this as “flakey,” should bear in mind that
the most successful and cost-effective treatment for
alcohol dependence remains the 12-step programs, such
as Alcoholics Anonymous (The Fellowship; Alcoholics
Anonymous World Services, 1984), and of course the
spiritual component lies at the very heart of this approach
(Corrington, 1989; Nathan, 1986). Spirituality retains a
place in contemporary psychiatry. It is not so long ago
that the Spirituality Special Interest Group became one
of the nine Special Interest Groups at the Royal College
of Psychiatry in London, and interest continues to grow.
It would be difficult to argue that all of these psychiatrists
are part of a lunatic fringe.
The United States is a country in which the
overwhelming majority of the population has some
spiritual beliefs. When one considers the high morbidity
and mortality from disorders such as alcohol dependence
and depression, it seems foolish to neglect all of the
opportunities for treatment which this circumstance
may offer. From a contemporary perspective, KPP is
less drastic than some of its alternatives, such as ECT
used for TRD and for which ketamine is sometimes
used as an anaesthetic (and may even be the source
of much of ECT’s purported effectiveness). It may be
time for a cultural shift in perceptions. With billions
of dollars at stake, it is understandable that some vested
interests may directly and/or indirectly lobby to oppose
any shift away from the culture of taking daily tablets
(or perhaps nasal sprays) and the use of ECT as the
ultimate psychiatric treatment. However, if protocols
develop which combine innovative methods, such as
KPP with ongoing maintenance alongside conventional
medicines as “standard practice,” some of the profitbased opposition may eventually lessen. Likewise,
opposition from both conservative factions that might
oppose any substance that can be seen as generating a
“high,” as well as by more spiritually liberal factions that
might denigrate such substances as less valid than using
so-called “natural” approaches (e.g., meditation), would
have to be confronted in the face of the tremendous
suffering that KPP could alleviate.
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